1
|
Casadio C, Tassinari E, Carloni R, Rossi R, Tenti MV, Fabbri L, Maltoni M. Appropriateness of Mini-Invasive Approaches for Nausea and Vomiting Refractory to Medical Therapy in Palliative Care Setting: A Case Report. Case Rep Oncol 2024; 17:264-270. [PMID: 38362443 PMCID: PMC10869145 DOI: 10.1159/000536218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2023] [Accepted: 01/03/2024] [Indexed: 02/17/2024] Open
Abstract
Introduction Nausea and vomiting are frequent multifactorial symptoms in oncological patients. These manifestations, mainly affecting the advanced disease stages, may lead to existential, psychological, and physical suffering, with a negative impact on the quality of life (QoL) of the individual and his family. The medical approach makes use of a wide range of drugs, with different antiemetic potency and various mechanisms of action, taking into account the etiology and the patient's response to the different therapeutic strategies. In recent years, in addition to pharmacological treatments, some endoscopic procedures have been integrated into clinical practice as promising palliative approaches. Case Presentation Herein, we describe and discuss a case of a 64-year-old female affected by advanced stage pancreatic adenocarcinoma, in which different techniques - both medical and endoscopic - have been used to approach a refractory symptomatology with a negative impact on the patient's QoL. In the context of a multidisciplinary approach in primary palliative care, a tailored intervention encompassing invasive methods for palliative purposes, may be considered adequate and appropriate when the prognostic expectation and the physical functionality indices allow it. Conclusion Minimally invasive palliative interventions should be offered to patients with advanced cancer when symptoms become refractory to standard medical therapies, as part of the holistic approach in modern treatments. Therefore, the integration of an early palliative approach into the patient's therapeutic path becomes essential for the management of all the individual's needs.
Collapse
Affiliation(s)
- Chiara Casadio
- Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Elisa Tassinari
- Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Riccardo Carloni
- Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Romina Rossi
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
| | | | - Laura Fabbri
- Palliative Care Unit, Azienda Unità Sanitaria Locale (AUSL) Romagna, Forli, Italy
| | - Marco Maltoni
- Palliative Care Unit, Azienda Unità Sanitaria Locale (AUSL) Romagna, Forli, Italy
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
| |
Collapse
|
2
|
Rega M, Andriani L, Poeta A, Casadio C, Diegoli G, Bonardi S, Conter M, Bacci C. Transmission of β-lactamases in the pork food chain: A public health concern. One Health 2023; 17:100632. [PMID: 38024261 PMCID: PMC10665163 DOI: 10.1016/j.onehlt.2023.100632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Revised: 09/11/2023] [Accepted: 09/21/2023] [Indexed: 12/01/2023] Open
Abstract
Antimicrobial resistance (AMR) is a risk for public health that requires management in a One Health perspective, including humans, animals, and the environment. The food production chain has been identified as a possible route of transmission of AMR bacteria to humans. The most critical issue regards resistance to the Critically Important Antimicrobials (CIAs), such as β-lactams antibiotics. Here, pigs were analysed along the entire food producing chain, including feces, carcasses and pork products (fresh meat, fermented and seasoned products) ensuring treaciability of all samples. Escherichia coli were isolated and their ability to produce ESBL and AmpC β-lactamases was evaluated both phenotypically and genotypically. Strains with the same AMR profile from feces, carcasses, and meat products were selected for phylogenetic and comparative genomic analyses to evaluate the possible "farm-to-fork" transmission of β-lactams resistant bacteria. Results showed that the percentage of ESBL strains in fecal E. coli was approximately 7% and increased slightly in the pork food chain: the 10% of ESBL E. coli isolated from carcasses and the 12.5% of isolates from fresh meat products. AmpC E. coli were found only in feces, carcasses, and fresh meat with a low prevalence. Results showed that of the 243 pigs followed along the entire food chain genetic similarities in E. coli isolated from farm-to-fork were found in only one pig (feces, carcasses and fresh meat). Frequent similarities were shown in resistant E. coli isolates from carcasses and fresh meat or fermented product (three pork food chain). Moreover, in one case, bacteria isolated from fresh meat and fermented product were genotypically similar. Concluding, direct transmission of β-lactams resistance from farm-to-fork is possible but not frequent. Further studies are needed to improve risk communication to consumers and access to clear and reliable information and health concerns on food.
Collapse
Affiliation(s)
- Martina Rega
- Food Hygiene and Inspection Unit, Veterinary Science Department, University of Parma, Strada del Taglio, 10, 43126 Parma, Italy
| | - Laura Andriani
- Food Hygiene and Inspection Unit, Veterinary Science Department, University of Parma, Strada del Taglio, 10, 43126 Parma, Italy
| | - Antonio Poeta
- Azienda Unità Sanitaria Locale (AUSL) sede Reggio Emilia, via Amendola 2, 42122 Reggio Emilia, Italy
| | - Chiara Casadio
- Azienda Unità Sanitaria Locale (AUSL) sede Modena, Via S. Giovanni del cantone, 23 41121 Modena, Italy
| | - Giuseppe Diegoli
- Emilia-Romagna Region, Collective Prevention and Public Health Service, viale Aldo Moro 21, 40127 Bologna, Italy
| | - Silvia Bonardi
- Food Hygiene and Inspection Unit, Veterinary Science Department, University of Parma, Strada del Taglio, 10, 43126 Parma, Italy
| | - Mauro Conter
- Food Hygiene and Inspection Unit, Veterinary Science Department, University of Parma, Strada del Taglio, 10, 43126 Parma, Italy
| | - Cristina Bacci
- Food Hygiene and Inspection Unit, Veterinary Science Department, University of Parma, Strada del Taglio, 10, 43126 Parma, Italy
| |
Collapse
|
3
|
Nigro MC, Marchese PV, Deiana C, Casadio C, Galvani L, Di Federico A, De Giglio A. Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review. Lung Cancer (Auckl) 2023; 14:11-25. [PMID: 36762267 PMCID: PMC9904307 DOI: 10.2147/lctt.s388047] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Accepted: 01/26/2023] [Indexed: 02/05/2023]
Abstract
Precision medicine has revolutionized the therapeutic management of cancer patients with a major impact on non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma, where advances have been remarkable. Tissue biopsy, required for tumor molecular testing, has significant limitations due to the difficulty of the biopsy site or the inadequacy of the histological specimen. In this context, liquid biopsy, consisting of the analysis of tumor-released materials circulating in body fluids, such as blood, is increasingly emerging as a valuable and non-invasive biomarker for detecting circulating tumor DNA (ctDNA) carrying molecular tumor signatures. In advanced/metastatic NSCLC, liquid biopsy drives target therapy by monitoring response to treatment and identifying eventual genomic mechanisms of resistance. In addition, recent data have shown a significant ability to detect minimal residual disease in early-stage lung cancer, underlying the potential application of liquid biopsy in the adjuvant setting, in early detection of recurrence, and also in the screening field. In this article, we present a review of the currently available data about the utility and application of liquid biopsy in lung cancer, with a particular focus on the approach to different techniques of analysis for liquid biopsy and a comparison with tissue samples as well as the potential practical uses in early and advanced/metastatic NSCLC.
Collapse
Affiliation(s)
- Maria Concetta Nigro
- Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi University Hospital, University of Bologna, Bologna, 40138, Italy
| | - Paola Valeria Marchese
- Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi University Hospital, University of Bologna, Bologna, 40138, Italy,Correspondence: Paola Valeria Marchese, Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi University Hospital, University of Bologna, Via Albertoni 15, Bologna, 40138, Italy, Email
| | - Chiara Deiana
- Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi University Hospital, University of Bologna, Bologna, 40138, Italy
| | - Chiara Casadio
- Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi University Hospital, University of Bologna, Bologna, 40138, Italy
| | - Linda Galvani
- Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi University Hospital, University of Bologna, Bologna, 40138, Italy
| | - Alessandro Di Federico
- Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi University Hospital, University of Bologna, Bologna, 40138, Italy
| | - Andrea De Giglio
- Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi University Hospital, University of Bologna, Bologna, 40138, Italy,Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, 40138, Italy
| |
Collapse
|
4
|
Vigliar E, Pisapia P, Dello Iacovo F, Alcaraz‐Mateos E, Alì G, Ali SZ, Baloch ZW, Bellevicine C, Bongiovanni M, Botsun P, Bruzzese D, Bubendorf L, Büttner R, Canberk S, Capitanio A, Casadio C, Cazacu E, Cochand‐Priollet B, D’Amuri A, Davis K, Eloy C, Engels M, Fadda G, Fontanini G, Fulciniti F, Hofman P, Iaccarino A, Ieni A, Jiang XS, Kakudo K, Kern I, Kholova I, Linton McDermott KM, Liu C, Lobo A, Lozano MD, Malapelle U, Maleki Z, Michelow P, Mikula MW, Musayev J, Özgün G, Oznur M, Peiró Marqués FM, Poller D, Pyzlak M, Robinson B, Rossi ED, Roy‐Chowdhuri S, Saieg M, Savic Prince S, Schmitt FC, Seguí Iváñez FJ, Štoos‐Veić T, Sulaieva O, Sweeney BJ, Tuccari G, van Velthuysen M, VanderLaan PA, Vielh P, Viola P, Voorham QJM, Weynand B, Zeppa P, Faquin WC, Pitman MB, Troncone G. COVID-19 pandemic impact on cytopathology practice in the post-lockdown period: An international, multicenter study. Cancer Cytopathol 2022; 130:344-351. [PMID: 35006650 PMCID: PMC9015399 DOI: 10.1002/cncy.22547] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2021] [Revised: 11/15/2021] [Accepted: 11/16/2021] [Indexed: 12/23/2022]
Abstract
BACKGROUND In a previous worldwide survey, the authors showed a drastic reduction in the number of cytological specimens processed during the coronavirus disease 2019 "lockdown" period along with an increase in malignancy rates. To assess the continued impact of the pandemic on cytological practices around the world, they undertook a second follow-up worldwide survey collecting data from the post-lockdown period (2020). METHODS Participants were asked to provide data regarding their cytopathology activity during the first 12 weeks of their respective national post-lockdown period (2020), which ranged from April 4 to October 31. Differences between the post-lockdown period and the corresponding 2019 period were evaluated, and the authors specifically focused on rates of malignant diagnoses. RESULTS A total of 29 respondents from 17 countries worldwide joined the survey. Overall, a lower number of cytological specimens (n = 236,352) were processed in comparison with the same period in 2019 (n = 321,466) for a relative reduction of 26.5%. The overall malignancy rate showed a statistically significant increase (12,442 [5.26%] vs 12,882 [4.01%]; P < .001) during the same time period. Similar results were obtained if both malignancy and suspicious for malignancy rates were considered together (15,759 [6.58%] vs 16,011 [4.98%]; P < .001). CONCLUSIONS The data showed a persistent reduction in the cytological specimen volume during the post-lockdown period (2020). However, the relative increase in the cytological workload in the late part of the post-lockdown is a promising finding of a slow return to normality.
Collapse
|
5
|
Gagliotti C, Bolzoni L, Carretto E, Sarti M, Ricchizzi E, Ambretti S, Barozzi A, Bracchi C, Confalonieri M, Menozzi I, Morganti M, Pedna MF, Sambri V, Scaltriti E, Schiavo R, Soliani L, Tambassi M, Venturelli C, Biagetti C, Buttazzi R, Calderaro A, Casadio C, Meschiari M, Tumietto F, Diegoli G, Pongolini S, Moro ML. Reduction trend of mcr-1 circulation in Emilia-Romagna Region, Italy. Eur J Clin Microbiol Infect Dis 2021; 40:2585-2592. [PMID: 34351529 DOI: 10.1007/s10096-021-04318-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2021] [Accepted: 07/19/2021] [Indexed: 10/20/2022]
Abstract
This study aims to describe trends of mcr-positive Enterobacterales in humans based on laboratory surveillance with a defined catchment population. The data source is the Micro-RER surveillance system, established in Emilia-Romagna region (Italy), to monitor the trend of mcr resistance. Enterobacterales isolates from human clinical samples with minimum inhibitory concentration (MIC) ≥ 2 mg/L for colistin were sent to the study reference laboratory for the detection of mcr genes. Isolates prospectively collected in the period 2018-2020 were considered for the assessment of population rates and trends; further analyses were carried out for the evaluation of clonality and horizontal mcr gene transfer. Previous isolates from local laboratory collection were also described. In the period 2018-2020, 1164 isolates were sent to the reference laboratory, and 51 (4.4%) were confirmed as mcr-positive: 50 mcr-1 (42 Escherichia coli, 6 Klebsiella pneumoniae, 2 Salmonella enterica) and 1 mcr-4 (Enterobacter cloacae). The number of mcr-positive isolates dropped from 24 in the first half of 2018 to 3 in the whole of 2020 (trend p value < 0.001). Genomic analyses showed the predominant role of the horizontal transfer of mcr genes through plasmids or dissemination of transposable elements compared to clonal dissemination of mcr-positive microorganisms. The study results demonstrate a substantial decrease in the circulation of mcr-1 plasmid genes in Emilia-Romagna Region.
Collapse
Affiliation(s)
- Carlo Gagliotti
- Agenzia Sanitaria e Sociale Regionale - Regione Emilia-Romagna, Viale Aldo Moro 21, 40127, Bologna, Italy.
| | - Luca Bolzoni
- Risk Analysis and Genomic Epidemiology, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna (IZSLER), Parma, Italy
| | | | | | - Enrico Ricchizzi
- Agenzia Sanitaria e Sociale Regionale - Regione Emilia-Romagna, Viale Aldo Moro 21, 40127, Bologna, Italy
| | - Simone Ambretti
- Unit of Microbiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, 40138, Bologna, Italy
| | | | - Chiara Bracchi
- Risk Analysis and Genomic Epidemiology, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna (IZSLER), Parma, Italy
| | | | - Ilaria Menozzi
- Risk Analysis and Genomic Epidemiology, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna (IZSLER), Parma, Italy
| | - Marina Morganti
- Risk Analysis and Genomic Epidemiology, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna (IZSLER), Parma, Italy
| | | | - Vittorio Sambri
- Microbiologia AUSL Romagna, Cesena, Italy
- DIMES, Università degli Studi di Bologna, Bologna, Italy
| | - Erika Scaltriti
- Risk Analysis and Genomic Epidemiology, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna (IZSLER), Parma, Italy
| | | | - Laura Soliani
- Risk Analysis and Genomic Epidemiology, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna (IZSLER), Parma, Italy
| | - Martina Tambassi
- Risk Analysis and Genomic Epidemiology, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna (IZSLER), Parma, Italy
| | | | | | - Rossella Buttazzi
- Agenzia Sanitaria e Sociale Regionale - Regione Emilia-Romagna, Viale Aldo Moro 21, 40127, Bologna, Italy
| | - Adriana Calderaro
- Department of Medicine and Surgery, University of Parma, Parma, Italy
| | - Chiara Casadio
- Servizio Prevenzione Collettiva e Sanità Pubblica, Direzione Generale Cura della Persona, Salute e Welfare, Bologna, Italy
| | | | - Fabio Tumietto
- Malattie infettive - IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Giuseppe Diegoli
- Servizio Prevenzione Collettiva e Sanità Pubblica, Direzione Generale Cura della Persona, Salute e Welfare, Bologna, Italy
| | - Stefano Pongolini
- Risk Analysis and Genomic Epidemiology, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna (IZSLER), Parma, Italy
| | - Maria Luisa Moro
- Agenzia Sanitaria e Sociale Regionale - Regione Emilia-Romagna, Viale Aldo Moro 21, 40127, Bologna, Italy
| |
Collapse
|
6
|
Nicosia L, Bozzini AC, Latronico A, Addante F, Mastropasqua MG, Meneghetti L, Mauri G, De Fiori E, Montesano M, Di Tonno C, Midolo De Luca V, Casadio C, Cassano E. COVID-19 and breast fine needle aspiration cytology method: What should we change? Cytopathology 2021; 32:312-317. [PMID: 33606300 PMCID: PMC8014188 DOI: 10.1111/cyt.12959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2020] [Revised: 12/28/2020] [Accepted: 01/13/2021] [Indexed: 11/26/2022]
Abstract
INTRODUCTION Air-dried slide preparation for fine needle aspiration cytology procedures is currently considered unsafe because of the risk of infectious aerosols of coronavirus 19. This study compares the safety and accuracy of two different protocols, one with and one without air-dried slides. METHODS Starting from 3 March 2020, we discontinued the use of air-dried slides during breast fine needle aspiration procedures. We selected cases collected during two periods: 2 months before and 2 months after 3 March. In both groups, the number of procedures was recorded together with the distribution of the diagnostic categories and the concordance between cytological and histological results on surgical specimens for lesions suggestive of malignancy, using the chi-squared test. RESULTS Of the 100 procedures performed during the pre-COVID-19 period, 55% were negative (C2), 3% were non-diagnostic (C1) and 40% were positive (C4 or C5). Of the 75 procedures obtained during the COVID-19 period, 44% were negative (C2), 2.7% were non-diagnostic (C1) and 52% were positive (C4 or C5). Despite the use of a new protocol during the COVID-19 period, we observed concordance between cytological and histological results for lesions suggestive of malignancy. There was no statistically significant difference concerning the distribution of the diagnostic categories in the two groups. CONCLUSIONS Taking into account the slightly lower number of procedures being analysed during the COVID-19 period, the introduction of a new protocol that does not include air-dried slides is safe and reliable.
Collapse
Affiliation(s)
- Luca Nicosia
- Department of Breast Radiology, IEO, European Institute of Oncology IRCCS, Milan, Italy
| | - Anna Carla Bozzini
- Department of Breast Radiology, IEO, European Institute of Oncology IRCCS, Milan, Italy
| | - Antuono Latronico
- Department of Breast Radiology, IEO, European Institute of Oncology IRCCS, Milan, Italy
| | - Francesca Addante
- Department of Emergency and Organ Transplants, School of Medicine, Section of Anatomic Pathology, University of Bari "Aldo Moro", Bari, Italy
| | - Mauro Giuseppe Mastropasqua
- Department of Emergency and Organ Transplants, School of Medicine, Section of Anatomic Pathology, University of Bari "Aldo Moro", Bari, Italy
| | - Lorenza Meneghetti
- Department of Breast Radiology, IEO, European Institute of Oncology IRCCS, Milan, Italy
| | - Giovanni Mauri
- Division of Interventional Radiology, IEO, European Institute of Oncology IRCCS, Milan, Italy
| | - Elvio De Fiori
- Department of Radiology, IEO, European Institute of Oncology IRCCS, Milan, Italy
| | - Marta Montesano
- Department of Breast Radiology, IEO, European Institute of Oncology IRCCS, Milan, Italy
| | - Clementina Di Tonno
- Division of Pathology and Laboratory Medicine, IEO, European Institute of Oncology IRCCS, Milan, Italy
| | - Valeria Midolo De Luca
- Division of Pathology and Laboratory Medicine, IEO, European Institute of Oncology IRCCS, Milan, Italy
| | - Chiara Casadio
- Division of Pathology and Laboratory Medicine, IEO, European Institute of Oncology IRCCS, Milan, Italy
| | - Enrico Cassano
- Department of Breast Radiology, IEO, European Institute of Oncology IRCCS, Milan, Italy
| |
Collapse
|
7
|
Vigliar E, Cepurnaite R, Alcaraz-Mateos E, Ali SZ, Baloch ZW, Bellevicine C, Bongiovanni M, Botsun P, Bruzzese D, Bubendorf L, Büttner R, Canberk S, Capitanio A, Casadio C, Cazacu E, Cochand-Priollet B, D'Amuri A, Eloy C, Engels M, Fadda G, Fontanini G, Fulciniti F, Hofman P, Iaccarino A, Ieni A, Jiang XS, Kakudo K, Kern I, Kholova I, Liu C, Lobo A, Lozano MD, Malapelle U, Maleki Z, Michelow P, Musayev J, Özgün G, Oznur M, Peiró Marqués FM, Pisapia P, Poller D, Pyzlak M, Robinson B, Rossi ED, Roy-Chowdhuri S, Saieg M, Savic Prince S, Schmitt FC, Javier Seguí Iváñez F, Štoos-Veić T, Sulaieva O, Sweeney BJ, Tuccari G, van Velthuysen ML, VanderLaan PA, Vielh P, Viola P, Voorham R, Weynand B, Zeppa P, Faquin WC, Pitman MB, Troncone G. Global impact of the COVID-19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries. Cancer Cytopathol 2020; 128:885-894. [PMID: 33108683 DOI: 10.1002/cncy.22373] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2020] [Revised: 09/14/2020] [Accepted: 09/16/2020] [Indexed: 11/08/2022]
Abstract
BACKGROUND To the authors' knowledge, the impact of the coronavirus disease 2019 (COVID-19) pandemic on cytopathology practices worldwide has not been investigated formally. In the current study, data from 41 respondents from 23 countries were reported. METHODS Data regarding the activity of each cytopathology laboratory during 4 weeks of COVID-19 lockdown were collected and compared with those obtained during the corresponding period in 2019. The overall number and percentage of exfoliative and fine-needle aspiration cytology samples from each anatomic site were recorded. Differences in the malignancy and suspicious rates between the 2 periods were analyzed using a meta-analytical approach. RESULTS Overall, the sample volume was lower compared with 2019 (104,319 samples vs 190,225 samples), with an average volume reduction of 45.3% (range, 0.1%-98.0%). The percentage of samples from the cervicovaginal tract, thyroid, and anorectal region was significantly reduced (P < .05). Conversely, the percentage of samples from the urinary tract, serous cavities, breast, lymph nodes, respiratory tract, salivary glands, central nervous system, gastrointestinal tract, pancreas, liver, and biliary tract increased (P < .05). An overall increase of 5.56% (95% CI, 3.77%-7.35%) in the malignancy rate in nongynecological samples during the COVID-19 pandemic was observed. When the suspicious category was included, the overall increase was 6.95% (95% CI, 4.63%-9.27%). CONCLUSIONS The COVID-19 pandemic resulted in a drastic reduction in the total number of cytology specimens regardless of anatomic site or specimen type. The rate of malignancy increased, reflecting the prioritization of patients with cancer who were considered to be at high risk. Prospective monitoring of the effect of delays in access to health services during the lockdown period is warranted.
Collapse
Affiliation(s)
- Elena Vigliar
- Department of Public Health, University of Naples Federico II, Naples, Italy
| | - Rima Cepurnaite
- Department of Public Health, University of Naples Federico II, Naples, Italy
| | - Eduardo Alcaraz-Mateos
- Pathology Department, Jose M. Morales Meseguer University General Hospital, Murcia, Spain
| | - Syed Z Ali
- Division of Cytopathology, Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland
| | - Zubair W Baloch
- Department of Pathology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Claudio Bellevicine
- Department of Public Health, University of Naples Federico II, Naples, Italy
| | | | | | - Dario Bruzzese
- Department of Public Health, University of Naples Federico II, Naples, Italy
| | - Lukas Bubendorf
- Institute of Pathology, University Hospital Basel, Basel, Switzerland
| | - Reinhard Büttner
- Department of Pathology, University Hospital Cologne, Cologne, Germany
| | - Sule Canberk
- Medical Faculty, IPATIMUP, Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal
| | - Arrigo Capitanio
- Department of Pathology, Linkoping University Hospital, Linkoping, Sweden
| | - Chiara Casadio
- Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
| | - Eugeniu Cazacu
- Department of Morphopathology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova
| | | | - Alessandro D'Amuri
- Anatomic Pathology Unit, A. Perrino Hospital, ASL Brindisi, Brindisi, Italy
| | - Catarina Eloy
- Medical Faculty, IPATIMUP, Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal
| | - Marianne Engels
- Department of Pathology, University Hospital Cologne, Cologne, Germany
| | - Guido Fadda
- Section of Pathological Anatomy, Department of Human Pathology "Gaetano Barresi", A.O.U. Polyclinic G. Martino, Messina, Italy
| | - Gabriella Fontanini
- Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy
| | - Franco Fulciniti
- Clinical Cytopathology Service, Histopathology Service, Cantonal Institute of Pathology, Locarno Cantonal Hospital, Locarno, Switzerland
| | - Paul Hofman
- Laboratory of Clinical and Experimental Pathology, Hospital-related Biobank (BB-0033-00025), FHU OncoAge, Pasteur Hospital, Nice, France
| | - Antonino Iaccarino
- Department of Public Health, University of Naples Federico II, Naples, Italy
| | - Antonio Ieni
- Section of Pathological Anatomy, Department of Human Pathology "Gaetano Barresi", A.O.U. Polyclinic G. Martino, Messina, Italy
| | - Xiaoyin Sara Jiang
- Department of Pathology, Duke University Medical Center, Durham, North Carolina
| | - Kennichi Kakudo
- Department of Pathology, Izumi City General Hospital, Izumi, Japan
| | | | - Ivana Kholova
- Department of Pathology, Fimlab Laboratories, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
| | - Chinhua Liu
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Anandi Lobo
- Department of Pathology, Kapoor Path Laboratories, Raipur, India
| | - Maria D Lozano
- Department of Pathology, University Clinic of Navarra, Pamplona, Spain
| | - Umberto Malapelle
- Department of Public Health, University of Naples Federico II, Naples, Italy
| | - Zahra Maleki
- Division of Cytopathology, Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland
| | - Pamela Michelow
- Department of Anatomical Pathology, University of the Witwatersrand, National Health Laboratory Service, Johannesburg, South Africa
| | | | - Gonca Özgün
- Department of Pathology, Baskent University Faculty of Medicine, Ankara, Turkey
| | - Meltem Oznur
- Department of Pathology, Tekirdag Namik Kemal University, Suleymanpaşa/Tekirdag, Turkey
| | | | - Pasquale Pisapia
- Department of Public Health, University of Naples Federico II, Naples, Italy
| | - David Poller
- Department of Pathology and Cytology, Queen Alexandra Hospital, Portsmouth, United Kingdom
| | | | - Betsy Robinson
- Department of Pathology, Duke University Medical Center, Durham, North Carolina
| | - Esther Diana Rossi
- Division of Anatomic Pathology and Histology, Catholic University-University Polyclinic Foundation "A. Gemini," Rome, Italy
| | - Sinchita Roy-Chowdhuri
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Mauro Saieg
- Department of Pathology, A.C. Camargo Cancer Center, Santa Casa Medical School, Sao Paulo, Brazil
| | | | - Fernando C Schmitt
- Medical Faculty, IPATIMUP, Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal
| | | | - Tajana Štoos-Veić
- Department of Pathology and Cytology, University Hospital Dubrava, Zagreb, Croatia
| | | | - Brenda J Sweeney
- Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - Giovanni Tuccari
- Section of Pathological Anatomy, Department of Human Pathology "Gaetano Barresi", A.O.U. Polyclinic G. Martino, Messina, Italy
| | | | - Paul A VanderLaan
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
| | | | - Patrizia Viola
- North West London Pathology, Imperial College Healthcare, NHS Trust Charing Cross Hospital, London, United Kingdom
| | - Rinus Voorham
- Quirinus JM Voorham, PALGA Foundation, Houten, The Netherlands
| | - Birgit Weynand
- Department of Pathology, University Hospitals Leuven, Leuven, Belgium
| | - Pio Zeppa
- Department of Medicine and Surgery, University of Salerno, Fisciano, Italy
| | - William C Faquin
- Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - Martha Bishop Pitman
- Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - Giancarlo Troncone
- Department of Public Health, University of Naples Federico II, Naples, Italy
| |
Collapse
|
8
|
Fumagalli C, Rappa A, Casadio C, Betella I, Colombo N, Barberis M, Guerini-Rocco E. Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis. J Clin Pathol 2019; 73:168-171. [DOI: 10.1136/jclinpath-2019-206127] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2019] [Revised: 09/02/2019] [Accepted: 09/04/2019] [Indexed: 01/12/2023]
Abstract
BackgroundWith the approval of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib for newly diagnosed, breast cancer gene (BRCA)1/2 mutated, ovarian cancer women, the assessment of BRCA1/2 tumour status will be shortly required at the time of diagnosis.AimTo investigate the feasibility of next-generation sequencing (NGS)-based BRCA tumour test on cytological specimens from ovarian cancer ascites.MethodsWe evaluated the BRCA1/2 status on neoplastic ascites and corresponding tumour tissue of 11 patients with ovarian cancer, using the NGS ‘Oncomine BRCA Research Assay’.ResultsThe NGS-based BRCA test on cytological samples had a success rate of 100%, with 11 of 11 concordant BRCA1/2 results between ascites and tumour tissues analyses, including two wild type samples and nine cases harbouring somatic or germline variants.ConclusionBRCA test may be performed on ovarian cancer ascites, reproducing BRCA1/2 tumour status and representing a useful tool for clinical decision-making.
Collapse
|
9
|
Ghirlanda G, Salafia OS, Paragi Z, Giroletti M, Yang J, Marcote B, Blanchard J, Agudo I, An T, Bernardini MG, Beswick R, Branchesi M, Campana S, Casadio C, Chassande-Mottin E, Colpi M, Covino S, D'Avanzo P, D'Elia V, Frey S, Gawronski M, Ghisellini G, Gurvits LI, Jonker PG, van Langevelde HJ, Melandri A, Moldon J, Nava L, Perego A, Perez-Torres MA, Reynolds C, Salvaterra R, Tagliaferri G, Venturi T, Vergani SD, Zhang M. Compact radio emission indicates a structured jet was produced by a binary neutron star merger. Science 2019; 363:968-971. [PMID: 30792360 DOI: 10.1126/science.aau8815] [Citation(s) in RCA: 197] [Impact Index Per Article: 39.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2018] [Accepted: 02/06/2019] [Indexed: 11/02/2022]
Abstract
The binary neutron star merger event GW170817 was detected through both electromagnetic radiation and gravitational waves. Its afterglow emission may have been produced by either a narrow relativistic jet or an isotropic outflow. High-spatial-resolution measurements of the source size and displacement can discriminate between these scenarios. We present very-long-baseline interferometry observations, performed 207.4 days after the merger by using a global network of 32 radio telescopes. The apparent source size is constrained to be smaller than 2.5 milli-arc seconds at the 90% confidence level. This excludes the isotropic outflow scenario, which would have produced a larger apparent size, indicating that GW170817 produced a structured relativistic jet. Our rate calculations show that at least 10% of neutron star mergers produce such a jet.
Collapse
Affiliation(s)
- G Ghirlanda
- Istituto Nazionale di Astrofisica-Osservatorio Astronomico di Brera, Via E. Bianchi 46, I-23807 Merate, Italy. .,Dipartimento di Fisica G. Occhialini, Università di Milano-Bicocca, Piazza della Scienza 3, IT-20126 Milano, Italy.,Sezione di Milano Bicocca, Istituto Nazionale Fisica Nucleare (INFN), Piazza della Scienza 3, 20126 Milano, Italy
| | - O S Salafia
- Istituto Nazionale di Astrofisica-Osservatorio Astronomico di Brera, Via E. Bianchi 46, I-23807 Merate, Italy. .,Dipartimento di Fisica G. Occhialini, Università di Milano-Bicocca, Piazza della Scienza 3, IT-20126 Milano, Italy.,Sezione di Milano Bicocca, Istituto Nazionale Fisica Nucleare (INFN), Piazza della Scienza 3, 20126 Milano, Italy
| | - Z Paragi
- Joint Institute for Very Long Baseline Interferometry (VLBI) European Research Infrastructure Consortium (ERIC), Oude Hoogeveensedijk 4, 7991 PD Dwingeloo, Netherlands
| | - M Giroletti
- Istituto Nazionale di Astrofisica-Istituto di Radioastronomia, via Gobetti 101, I40129, Bologna, Italia
| | - J Yang
- Chalmers University of Technology, Onsala Space Observatory, SE-439 92, Sweden.,Yunnan Observatories, Chinese Academy of Sciences, 650216 Kunming, Yunnan, China
| | - B Marcote
- Joint Institute for Very Long Baseline Interferometry (VLBI) European Research Infrastructure Consortium (ERIC), Oude Hoogeveensedijk 4, 7991 PD Dwingeloo, Netherlands
| | - J Blanchard
- Joint Institute for Very Long Baseline Interferometry (VLBI) European Research Infrastructure Consortium (ERIC), Oude Hoogeveensedijk 4, 7991 PD Dwingeloo, Netherlands
| | - I Agudo
- Instituto de Astrofísica de Andalucía-Consejo Superior de Investigaciones Científicas (CSIC), Glorieta de la Astronomía s/n, E-18008, Granada, Spain
| | - T An
- Shanghai Astronomical Observatory, Key Laboratory of Radio Astronomy, Chinese Academy of Sciences, 200030 Shanghai, China
| | - M G Bernardini
- Laboratoire Univers et Particules de Montpellier, Universitè de Montpellier, Centre National de la Recherche Scientifique/Institute National de Physique Nucleaire et Physique des Particules (CNRS/IN2P3), place Eugéne Bataillon, F-34085 Montpellier, France
| | - R Beswick
- Electronic Multi-Element Radio Linked Interferometer Network/Very Long Baseline Interferometry (e-MERLIN/VLBI) National Facility, Jodrell Bank Centre for Astrophysics, School of Physics and Astronomy, University of Manchester, Manchester, UK
| | - M Branchesi
- Gran Sasso Science Institute, Viale F. Crispi 7, I-67100, L'Aquila, Italy.,Laboratori Nazionali del Gran Sasso, INFN, I-67100 L'Aquila, Italy
| | - S Campana
- Istituto Nazionale di Astrofisica-Osservatorio Astronomico di Brera, Via E. Bianchi 46, I-23807 Merate, Italy
| | - C Casadio
- Max Planck Institute fur Radioastronomie, Auf dem Huegel 69, Bonn D-53121, Germany
| | - E Chassande-Mottin
- AstroParticule et Cosmologie (APC), Université Paris Diderot, CNRS/IN2P3, Commissariat à l'Énergie Atomique et aux Énergies Alternatives/ Institute for Research on the Fundamental Laws of the Universe (CEA/IRFU), Observatoire de Paris, Sorbonne Paris Cité, F-75205 Paris Cedex 13, France
| | - M Colpi
- Dipartimento di Fisica G. Occhialini, Università di Milano-Bicocca, Piazza della Scienza 3, IT-20126 Milano, Italy.,Sezione di Milano Bicocca, Istituto Nazionale Fisica Nucleare (INFN), Piazza della Scienza 3, 20126 Milano, Italy
| | - S Covino
- Istituto Nazionale di Astrofisica-Osservatorio Astronomico di Brera, Via E. Bianchi 46, I-23807 Merate, Italy
| | - P D'Avanzo
- Istituto Nazionale di Astrofisica-Osservatorio Astronomico di Brera, Via E. Bianchi 46, I-23807 Merate, Italy
| | - V D'Elia
- Space Science Data Center, Agenzia Spaziale Italiana (ASI), Via del Politecnico, 00133, Roma, Italy
| | - S Frey
- Konkoly Observatory, Magyar Tudományos Akadémia (MTA) Research Centre for Astronomy and Earth Sciences, Konkoly Thege Miklós út 15-17, H-1121 Budapest, Hungary
| | - M Gawronski
- Centre for Astronomy, Faculty of Physics, Astronomy and Informatics, Nicolaus Copernicus University, Grudziadzka 5, 87-100 Torun, Poland
| | - G Ghisellini
- Istituto Nazionale di Astrofisica-Osservatorio Astronomico di Brera, Via E. Bianchi 46, I-23807 Merate, Italy
| | - L I Gurvits
- Joint Institute for Very Long Baseline Interferometry (VLBI) European Research Infrastructure Consortium (ERIC), Oude Hoogeveensedijk 4, 7991 PD Dwingeloo, Netherlands.,Department of Astrodynamics and Space Missions, Delft University of Technology, Kluyverweg 1, 2629 HS Delft, Netherlands
| | - P G Jonker
- Space Research Organisation of the Netherlands (SRON), Netherlands Institute for Space Research, Sorbonnelaan 2, 3584 CA Utrecht, Netherlands.,Department of Astrophysics, Institute for Mathematics, Astrophysics and Particle Physics (IMAPP), Radboud University, Post Office Box 9010, 6500 GL Nijmegen, Netherlands
| | - H J van Langevelde
- Joint Institute for Very Long Baseline Interferometry (VLBI) European Research Infrastructure Consortium (ERIC), Oude Hoogeveensedijk 4, 7991 PD Dwingeloo, Netherlands.,Sterrewacht Leiden, Leiden University, Post Office Box 9513, NL-2300 RA Leiden, Netherlands
| | - A Melandri
- Istituto Nazionale di Astrofisica-Osservatorio Astronomico di Brera, Via E. Bianchi 46, I-23807 Merate, Italy
| | - J Moldon
- Electronic Multi-Element Radio Linked Interferometer Network/Very Long Baseline Interferometry (e-MERLIN/VLBI) National Facility, Jodrell Bank Centre for Astrophysics, School of Physics and Astronomy, University of Manchester, Manchester, UK
| | - L Nava
- Istituto Nazionale di Astrofisica-Osservatorio Astronomico di Brera, Via E. Bianchi 46, I-23807 Merate, Italy
| | - A Perego
- Sezione di Milano Bicocca, Istituto Nazionale Fisica Nucleare (INFN), Piazza della Scienza 3, 20126 Milano, Italy
| | - M A Perez-Torres
- Instituto de Astrofísica de Andalucía-Consejo Superior de Investigaciones Científicas (CSIC), Glorieta de la Astronomía s/n, E-18008, Granada, Spain.,Departamento de Física Teórica, Facultad de Ciencias, Universidad de Zaragoza, E-50019, Spain
| | - C Reynolds
- Commonwealth Scientific and Industrial Research Organization (CSIRO) Astronomy and Space Science, PO Box 1130, Bentley WA 6102, Australia
| | - R Salvaterra
- Istituto Nazionale di Astrofisica, Istituto di Astrofisica Spaziale e Fisica cosmica (IASF), via E. Bassini 15, 20133 Milano, Italy
| | - G Tagliaferri
- Istituto Nazionale di Astrofisica-Osservatorio Astronomico di Brera, Via E. Bianchi 46, I-23807 Merate, Italy
| | - T Venturi
- Istituto Nazionale di Astrofisica-Istituto di Radioastronomia, via Gobetti 101, I40129, Bologna, Italia
| | - S D Vergani
- Galaxies, Etoiles, Physique et Instrumentation (GEPI) Observatoire de Paris, CNRS UMR 8111, Meudon, France
| | - M Zhang
- Xinjiang Astronomical Observatory, Chinese Academy of Sciences, 150 Science 1-Street, Urumqi 831001, China.,Key Laboratory for Radio Astronomy, Chinese Academy of Sciences, 2 West Beijing Road, Nanjing 210008, China
| |
Collapse
|
10
|
Guerini-Rocco E, Passaro A, Casadio C, De Luca VM, Guarize J, de Marinis F, Vacirca D, Barberis M. Acquired Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples. Arch Pathol Lab Med 2019; 142:465-473. [PMID: 29565206 DOI: 10.5858/arpa.2017-0158-ra] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
CONTEXT - Molecular testing is essential for the diagnostic workup of patients with advanced non-small cell lung cancers. Cytology specimens from minimally invasive procedures, such as endobronchial ultrasound-guided transbronchial needle aspiration, are often the only available samples for these patients. The implementation of molecular diagnostic testing, and in particular next-generation sequencing-based testing, on these cytologic specimens is currently an evolving field for lung cytopathology. The application of these molecular analyses on tyrosine kinase inhibitor-resistant non-small cell lung cancers raises unique technical, biologic, and clinical challenges. OBJECTIVE - To provide an overview of the implementation of next-generation sequencing analysis on endobronchial ultrasound-guided transbronchial needle aspiration samples to detect the molecular aberrations underneath the phenomenon of acquired resistance in patients with non-small cell lung cancers progressing while on the EGFR/ALK tyrosine kinase inhibitor treatment. DATA SOURCES - Peer-reviewed original articles, review articles, and published guidelines and expert opinion reports were reviewed, together with our single-center experience. CONCLUSIONS - Next-generation sequencing analyses and the endobronchial ultrasound-guided transbronchial needle aspiration procedure may represent a valuable strategy to address the unique requirements of molecular testing on tyrosine kinase inhibitor-resistant non-small cell lung cancers.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Massimo Barberis
- From the Divisions of Pathology (Drs Guerini-Rocco, Casadio, Midolo De Luca, and Barberis, and Mr Vacirca), Thoracic Oncology (Drs Passaro and de Marinis), and Thoracic Surgery (Dr Guarize), European Institute of Oncology, Milan, Italy
| |
Collapse
|
11
|
Abstract
The sensitivity of a new tumor marker, TA 4-SCC, for lung tumors is examined and compared with the performance of the already established CEA. TA 4-SCC sensitivity is only moderate (30 %), and it presents no significant differences among the various histologic types of lung cancer. In addition, unlike CEA, TA 4-SCC is present in large amounts in the serum of many stage I and II patients. In fact, its sensitivity in still curatively operable tumors reaches 30 % compared to 10 % with CEA.
Collapse
Affiliation(s)
- F Pecchio
- Laboratorio Baldi e Riberi, Ospedale S. Giovanni Battista, Torino, Italia
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Fumagalli C, Vacirca D, Rappa A, Passaro A, Guarize J, Rafaniello Raviele P, de Marinis F, Spaggiari L, Casadio C, Viale G, Barberis M, Guerini-Rocco E. The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics. J Clin Pathol 2018. [PMID: 29535211 DOI: 10.1136/jclinpath-2018-205032] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
BACKGROUND Molecular profiling of advanced non-small cell lung cancers (NSCLC) is essential to identify patients who may benefit from targeted treatments. In the last years, the number of potentially actionable molecular alterations has rapidly increased. Next-generation sequencing allows for the analysis of multiple genes simultaneously. AIMS To evaluate the feasibility and the throughput of next-generation sequencing in clinical molecular diagnostics of advanced NSCLC. METHODS A single-institution cohort of 535 non-squamous NSCLC was profiled using a next-generation sequencing panel targeting 22 actionable and cancer-related genes. RESULTS 441 non-squamous NSCLC (82.4%) harboured at least one gene alteration, including 340 cases (63.6%) with clinically relevant molecular aberrations. Mutations have been detected in all but one gene (FGFR1) of the panel. Recurrent alterations were observed in KRAS, TP53, EGFR, STK11 and MET genes, whereas the remaining genes were mutated in <5% of the cases. Concurrent mutations were detected in 183 tumours (34.2%), mostly impairing KRAS or EGFR in association with TP53 alterations. CONCLUSIONS The study highlights the feasibility of targeted next-generation sequencing in clinical setting. The majority of NSCLC harboured mutations in clinically relevant genes, thus identifying patients who might benefit from different targeted therapies.
Collapse
Affiliation(s)
- Caterina Fumagalli
- Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
| | - Davide Vacirca
- Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
| | - Alessandra Rappa
- Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
| | - Antonio Passaro
- Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy
| | - Juliana Guarize
- Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
| | | | - Filippo de Marinis
- Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy
| | - Lorenzo Spaggiari
- Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy.,Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - Chiara Casadio
- Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
| | - Giuseppe Viale
- Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy.,Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - Massimo Barberis
- Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
| | - Elena Guerini-Rocco
- Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy.,Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| |
Collapse
|
13
|
Fumagalli C, Casadio C, Barberis M, Guarize J, Guerini-Rocco E. Letter to the Editor. Clin Lung Cancer 2018; 19:e439-e440. [PMID: 29606366 DOI: 10.1016/j.cllc.2018.03.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2018] [Accepted: 03/04/2018] [Indexed: 11/17/2022]
Affiliation(s)
- Caterina Fumagalli
- Division of Pathology and Laboratory Medicine, Istituto Europeo di Oncologia, Milan, Italy
| | - Chiara Casadio
- Division of Pathology and Laboratory Medicine, Istituto Europeo di Oncologia, Milan, Italy
| | - Massimo Barberis
- Division of Pathology and Laboratory Medicine, Istituto Europeo di Oncologia, Milan, Italy.
| | - Juliana Guarize
- Division of Thoracic Surgery, Istituto Europeo di Oncologia, Milan, Italy
| | - Elena Guerini-Rocco
- Division of Pathology and Laboratory Medicine, Istituto Europeo di Oncologia, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| |
Collapse
|
14
|
De Censi A, Cazzaniga M, Gandini S, Casadio C, Chiapparini L, Guerrieri-Gonzaga A, Macis D, Veronesi P, Bonanni B. Abstract P3-10-02: Presence of atypia in ductal lavage and risk of subsequent breast cancer in a prospective study. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-10-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Atypical hyperplasia is considered a nearly obligate precursor of breast cancer and is associated with a higher risk of developing breast cancer (BC). Attempts to improve early detection of breast cancer and to provide individualized breast cancer risk assessment would greatly benefit from sampling cellular material from the target tissue. Ductal lavage (DL) is a minimally invasive technique which provides adequate material to detect atypical cells in mammary ducts. However, long term data of the association between atypia from ductal lavage and BC risk are lacking. We studied the prevalence of atypia in DL in different risk categories and its ability to predict BC development in women at risk. Methods: From March 2000 to July 2012 we performed DL in a consecutive series of 348 women with median age of 45 years (range 19-74) at increased BC risk based on the following characteristics: 5 yrs Gail model > 1.66% or > 10% probability of BRCA mutation (n = 155), history of contralateral BC (CBC, n = 161), presence of a BRCA pathogenic variant (n = 32). We analyzed the presence of atypical cells in the baseline specimen of ductal lavage and in repeated lavage and observed their evolution during follow-up. Results: The procedure was safe and well tolerated in most women, with pain and disconfort preventing the procedure in 5.4% of subjects. Overall, 126 (36%) women had atypia at baseline, with a prevalence of 32%, 39%, and 41% in the Gail, CBC and BRCA groups, respectively (p = 0.38). The overall prevalence of atypia considering all visits was 44% (range 36-51). After a median follow up of 6 years, cumulative BC events were 8% in women without atypia versus 14% in those with atypia (log-rank p = 0.08). In the highest risk groups (CBC and BRCA pathogenic variants), the number of BC events was 16 (21%) in women with atypia versus 11 (10%) in women without atypia (p = 0.02 after adjustment for age). Conclusions: Our findings suggest that cytologic atypia in the fluid obtained by DL predicts subsequent BC in women at increased risk, providing individual risk assessment. The reversal of atypia in DL should be evaluated as a surrogate biomarker of BC therapeutic prevention.
Supported by: Associazione Italiana per la Ricerca sul Cancro (AIRC), Lega Italina per la Lotta contro i Tumori (LILT), AVON Foundation for Women.
Citation Format: De Censi A, Cazzaniga M, Gandini S, Casadio C, Chiapparini L, Guerrieri-Gonzaga A, Macis D, Veronesi P, Bonanni B. Presence of atypia in ductal lavage and risk of subsequent breast cancer in a prospective study [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-10-02.
Collapse
Affiliation(s)
- A De Censi
- Ospedali Galliera, Genova, Italy; Queen Mary University, London, United Kingdom; IEO-Istituto Europeo di Oncologia, Milano, Italy
| | - M Cazzaniga
- Ospedali Galliera, Genova, Italy; Queen Mary University, London, United Kingdom; IEO-Istituto Europeo di Oncologia, Milano, Italy
| | - S Gandini
- Ospedali Galliera, Genova, Italy; Queen Mary University, London, United Kingdom; IEO-Istituto Europeo di Oncologia, Milano, Italy
| | - C Casadio
- Ospedali Galliera, Genova, Italy; Queen Mary University, London, United Kingdom; IEO-Istituto Europeo di Oncologia, Milano, Italy
| | - L Chiapparini
- Ospedali Galliera, Genova, Italy; Queen Mary University, London, United Kingdom; IEO-Istituto Europeo di Oncologia, Milano, Italy
| | - A Guerrieri-Gonzaga
- Ospedali Galliera, Genova, Italy; Queen Mary University, London, United Kingdom; IEO-Istituto Europeo di Oncologia, Milano, Italy
| | - D Macis
- Ospedali Galliera, Genova, Italy; Queen Mary University, London, United Kingdom; IEO-Istituto Europeo di Oncologia, Milano, Italy
| | - P Veronesi
- Ospedali Galliera, Genova, Italy; Queen Mary University, London, United Kingdom; IEO-Istituto Europeo di Oncologia, Milano, Italy
| | - B Bonanni
- Ospedali Galliera, Genova, Italy; Queen Mary University, London, United Kingdom; IEO-Istituto Europeo di Oncologia, Milano, Italy
| |
Collapse
|
15
|
Guarize J, Bianchi F, Marino E, Belloni E, Vecchi M, Donghi S, Lo Iacono G, Casadio C, Cuttano R, Barberis M, Di Fiore PP, Petrella F, Spaggiari L. MicroRNA expression profile in primary lung cancer cells lines obtained by endobronchial ultrasound transbronchial needle aspiration. J Thorac Dis 2018; 10:408-415. [PMID: 29600073 DOI: 10.21037/jtd.2017.12.69] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Background Novel cancer biomarkers like microRNA (miRNA) are promising tools to gain a better understanding of lung cancer pathology and yield important information to guide therapy. In recent years, new less invasive methods for the diagnosis and staging of NSCLC have become key tools in thoracic oncology and the worldwide spread of endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA). However, appropriate specimen handling is mandatory to achieve adequate results and reproducibility. The aim of this single centre prospective study was to evaluate the feasibility of a complete miRNA expression profile in fresh NSCLC cell lines obtained by EBUS-TBNA. Methods Patients with proven NSCLC underwent EBUS-TBNA for the diagnosis of suspect lymph node metastasis, and cytological specimens were collected for epithelial cell culture and miRNA expression analysis. To validate the miRNA expression profile, we compared the results from EBUS-TBNA NSCLC specimens with those obtained from formalin-fixed paraffin-embedded (FFPE) mediastinoscopy specimens. Results Analysis of the miRNA expression profiles of three independent EBUS-TBNA-derived primary cell lines allowed the screening of 377 different human miRNAs. One hundred and fifty miRNAs were detected in all cell lines. Analysis of the miRNA expression profile in mediastinoscopy specimens showed a strong similarity in the clusters analysed. Conclusions The miRNA expression profile is feasible and reliable in EBUS-TBNA specimens. Validation of this protocol in fresh cytological specimens represents an effective and reproducible method to correlate translational and clinical research.
Collapse
Affiliation(s)
- Juliana Guarize
- Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
| | - Fabrizio Bianchi
- Molecular Medicine Program, European Institute of Oncology, Milan, Italy.,ISBReMIT, Institute for Stem-cell Biology, Regenerative Medicine and Innovative Therapies, Casa Sollievo della Sofferenza-IRCCS, San Giovanni Rotondo, Italy
| | - Elena Marino
- Molecular Medicine Program, European Institute of Oncology, Milan, Italy.,Clinical Genomics Unit, European Institute of Oncology, Milan, Italy
| | - Elena Belloni
- Molecular Medicine Program, European Institute of Oncology, Milan, Italy.,Clinical Genomics Unit, European Institute of Oncology, Milan, Italy
| | - Manuela Vecchi
- Molecular Medicine Program, European Institute of Oncology, Milan, Italy.,IFOM, the FIRC Institute of Molecular Oncology, Milan, Italy
| | - Stefano Donghi
- Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
| | - Giorgio Lo Iacono
- Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
| | - Chiara Casadio
- Division of Pathology, European Institute of Oncology, Milan, Italy
| | - Roberto Cuttano
- ISBReMIT, Institute for Stem-cell Biology, Regenerative Medicine and Innovative Therapies, Casa Sollievo della Sofferenza-IRCCS, San Giovanni Rotondo, Italy
| | - Massimo Barberis
- Division of Pathology, European Institute of Oncology, Milan, Italy
| | - Pier Paolo Di Fiore
- Molecular Medicine Program, European Institute of Oncology, Milan, Italy.,IFOM, the FIRC Institute of Molecular Oncology, Milan, Italy.,Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - Francesco Petrella
- Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy.,Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - Lorenzo Spaggiari
- Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy.,Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| |
Collapse
|
16
|
Raiteri CM, Villata M, Acosta-Pulido JA, Agudo I, Arkharov AA, Bachev R, Baida GV, Benítez E, Borman GA, Boschin W, Bozhilov V, Butuzova MS, Calcidese P, Carnerero MI, Carosati D, Casadio C, Castro-Segura N, Chen WP, Damljanovic G, D'Ammando F, Di Paola A, Echevarría J, Efimova NV, Ehgamberdiev SA, Espinosa C, Fuentes A, Giunta A, Gómez JL, Grishina TS, Gurwell MA, Hiriart D, Jermak H, Jordan B, Jorstad SG, Joshi M, Kopatskaya EN, Kuratov K, Kurtanidze OM, Kurtanidze SO, Lähteenmäki A, Larionov VM, Larionova EG, Larionova LV, Lázaro C, Lin CS, Malmrose MP, Marscher AP, Matsumoto K, McBreen B, Michel R, Mihov B, Minev M, Mirzaqulov DO, Mokrushina AA, Molina SN, Moody JW, Morozova DA, Nazarov SV, Nikolashvili MG, Ohlert JM, Okhmat DN, Ovcharov E, Pinna F, Polakis TA, Protasio C, Pursimo T, Redondo-Lorenzo FJ, Rizzi N, Rodriguez-Coira G, Sadakane K, Sadun AC, Samal MR, Savchenko SS, Semkov E, Skiff BA, Slavcheva-Mihova L, Smith PS, Steele IA, Strigachev A, Tammi J, Thum C, Tornikoski M, Troitskaya YV, Troitsky IS, Vasilyev AA, Vince O. Blazar spectral variability as explained by a twisted inhomogeneous jet. Nature 2017; 552:374-377. [PMID: 29211720 DOI: 10.1038/nature24623] [Citation(s) in RCA: 85] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2017] [Accepted: 10/06/2017] [Indexed: 11/09/2022]
Abstract
Blazars are active galactic nuclei, which are powerful sources of radiation whose central engine is located in the core of the host galaxy. Blazar emission is dominated by non-thermal radiation from a jet that moves relativistically towards us, and therefore undergoes Doppler beaming. This beaming causes flux enhancement and contraction of the variability timescales, so that most blazars appear as luminous sources characterized by noticeable and fast changes in brightness at all frequencies. The mechanism that produces this unpredictable variability is under debate, but proposed mechanisms include injection, acceleration and cooling of particles, with possible intervention of shock waves or turbulence. Changes in the viewing angle of the observed emitting knots or jet regions have also been suggested as an explanation of flaring events and can also explain specific properties of blazar emission, such as intra-day variability, quasi-periodicity and the delay of radio flux variations relative to optical changes. Such a geometric interpretation, however, is not universally accepted because alternative explanations based on changes in physical conditions-such as the size and speed of the emitting zone, the magnetic field, the number of emitting particles and their energy distribution-can explain snapshots of the spectral behaviour of blazars in many cases. Here we report the results of optical-to-radio-wavelength monitoring of the blazar CTA 102 and show that the observed long-term trends of the flux and spectral variability are best explained by an inhomogeneous, curved jet that undergoes changes in orientation over time. We propose that magnetohydrodynamic instabilities or rotation of the twisted jet cause different jet regions to change their orientation and hence their relative Doppler factors. In particular, the extreme optical outburst of 2016-2017 (brightness increase of six magnitudes) occurred when the corresponding emitting region had a small viewing angle. The agreement between observations and theoretical predictions can be seen as further validation of the relativistic beaming theory.
Collapse
Affiliation(s)
- C M Raiteri
- INAF, Osservatorio Astrofisico di Torino, I-10025 Pino Torinese, Italy
| | - M Villata
- INAF, Osservatorio Astrofisico di Torino, I-10025 Pino Torinese, Italy
| | - J A Acosta-Pulido
- Instituto de Astrofisica de Canarias (IAC), La Laguna, E-38200 Tenerife, Spain.,Departamento de Astrofisica, Universidad de La Laguna, La Laguna, E-38205 Tenerife, Spain
| | - I Agudo
- Instituto de Astrofísica de Andalucía (CSIC), E-18080 Granada, Spain
| | - A A Arkharov
- Pulkovo Observatory, 196140 St Petersburg, Russia
| | - R Bachev
- Institute of Astronomy and NAO, Bulgarian Academy of Sciences, 1784 Sofia, Bulgaria
| | - G V Baida
- Crimean Astrophysical Observatory RAS, Nauchny 298409, Russia
| | - E Benítez
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Mexico
| | - G A Borman
- Crimean Astrophysical Observatory RAS, Nauchny 298409, Russia
| | - W Boschin
- Instituto de Astrofisica de Canarias (IAC), La Laguna, E-38200 Tenerife, Spain.,Departamento de Astrofisica, Universidad de La Laguna, La Laguna, E-38205 Tenerife, Spain.,INAF, TNG Fundación Galileo Galilei, E-38712 La Palma, Spain
| | - V Bozhilov
- Department of Astronomy, Faculty of Physics, University of Sofia, BG-1164 Sofia, Bulgaria
| | - M S Butuzova
- Crimean Astrophysical Observatory RAS, Nauchny 298409, Russia
| | - P Calcidese
- Osservatorio Astronomico della Regione Autonoma Valle d'Aosta, I-11020 Nus, Italy
| | - M I Carnerero
- INAF, Osservatorio Astrofisico di Torino, I-10025 Pino Torinese, Italy
| | - D Carosati
- INAF, TNG Fundación Galileo Galilei, E-38712 La Palma, Spain.,EPT Observatories, Tijarafe, E-38780 La Palma, Spain
| | - C Casadio
- Instituto de Astrofísica de Andalucía (CSIC), E-18080 Granada, Spain.,Max-Planck-Institut für Radioastronomie, D-53121 Bonn, Germany
| | - N Castro-Segura
- Departamento de Astrofisica, Universidad de La Laguna, La Laguna, E-38205 Tenerife, Spain.,School of Physics and Astronomy, University of Southampton, Southampton SO17 1BJ, UK
| | - W-P Chen
- Graduate Institute of Astronomy, National Central University, Jhongli City, Taoyuan County 32001, Taiwan
| | | | - F D'Ammando
- Dipartimento di Fisica e Astronomia, Università di Bologna, I-40129 Bologna, Italy.,INAF, Istituto di Radioastronomia, I-40129 Bologna, Italy
| | - A Di Paola
- INAF, Osservatorio Astronomico di Roma, I-00040 Monte Porzio Catone, Italy
| | - J Echevarría
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Mexico
| | - N V Efimova
- Pulkovo Observatory, 196140 St Petersburg, Russia
| | - Sh A Ehgamberdiev
- Ulugh Beg Astronomical Institute, Maidanak Observatory, Tashkent 100052, Uzbekistan
| | - C Espinosa
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Mexico
| | - A Fuentes
- Instituto de Astrofísica de Andalucía (CSIC), E-18080 Granada, Spain
| | - A Giunta
- INAF, Osservatorio Astronomico di Roma, I-00040 Monte Porzio Catone, Italy
| | - J L Gómez
- Instituto de Astrofísica de Andalucía (CSIC), E-18080 Granada, Spain
| | - T S Grishina
- Astronomical Institute, St Petersburg State University, 198504 St Petersburg, Russia
| | - M A Gurwell
- Harvard-Smithsonian Center for Astrophysics, Cambridge, Massachusetts 02138, USA
| | - D Hiriart
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Mexico
| | - H Jermak
- Astrophysics Research Institute, Liverpool John Moores University, Liverpool L3 5RF, UK
| | - B Jordan
- School of Cosmic Physics, Dublin Institute For Advanced Studies, Dublin, Ireland
| | - S G Jorstad
- Astronomical Institute, St Petersburg State University, 198504 St Petersburg, Russia.,Institute for Astrophysical Research, Boston University, Boston, Massachusetts 02215, USA
| | - M Joshi
- Institute for Astrophysical Research, Boston University, Boston, Massachusetts 02215, USA
| | - E N Kopatskaya
- Astronomical Institute, St Petersburg State University, 198504 St Petersburg, Russia
| | - K Kuratov
- NNLOT, Al-Farabi Kazakh National University, Almaty, Kazakhstan.,Fesenkov Astrophysical Institute, Almaty, Kazakhstan
| | - O M Kurtanidze
- Abastumani Observatory, Mt Kanobili, 0301 Abastumani, Georgia.,Engelhardt Astronomical Observatory, Kazan Federal University, Tatarstan, Russia.,Landessternwarte, Zentrum für Astronomie der Universität Heidelberg, 69117 Heidelberg, Germany.,Center for Astrophysics, Guangzhou University, Guangzhou 510006, China
| | - S O Kurtanidze
- Abastumani Observatory, Mt Kanobili, 0301 Abastumani, Georgia
| | - A Lähteenmäki
- Aalto University Metsähovi Radio Observatory, FI-02540 Kylmälä, Finland.,Aalto University Department of Electronics and Nanoengineering, FI-00076 Aalto, Finland.,Tartu Observatory, 61602 Tõravere, Estonia
| | - V M Larionov
- Pulkovo Observatory, 196140 St Petersburg, Russia.,Astronomical Institute, St Petersburg State University, 198504 St Petersburg, Russia
| | - E G Larionova
- Astronomical Institute, St Petersburg State University, 198504 St Petersburg, Russia
| | - L V Larionova
- Astronomical Institute, St Petersburg State University, 198504 St Petersburg, Russia
| | - C Lázaro
- Instituto de Astrofisica de Canarias (IAC), La Laguna, E-38200 Tenerife, Spain.,Departamento de Astrofisica, Universidad de La Laguna, La Laguna, E-38205 Tenerife, Spain
| | - C S Lin
- Graduate Institute of Astronomy, National Central University, Jhongli City, Taoyuan County 32001, Taiwan
| | - M P Malmrose
- Institute for Astrophysical Research, Boston University, Boston, Massachusetts 02215, USA
| | - A P Marscher
- Institute for Astrophysical Research, Boston University, Boston, Massachusetts 02215, USA
| | - K Matsumoto
- Astronomical Institute, Osaka Kyoiku University, Osaka 582-8582, Japan
| | - B McBreen
- School of Physics, University College Dublin, Dublin 4, Ireland
| | - R Michel
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Mexico
| | - B Mihov
- Institute of Astronomy and NAO, Bulgarian Academy of Sciences, 1784 Sofia, Bulgaria
| | - M Minev
- Department of Astronomy, Faculty of Physics, University of Sofia, BG-1164 Sofia, Bulgaria
| | - D O Mirzaqulov
- Ulugh Beg Astronomical Institute, Maidanak Observatory, Tashkent 100052, Uzbekistan
| | - A A Mokrushina
- Pulkovo Observatory, 196140 St Petersburg, Russia.,Astronomical Institute, St Petersburg State University, 198504 St Petersburg, Russia
| | - S N Molina
- Instituto de Astrofísica de Andalucía (CSIC), E-18080 Granada, Spain
| | - J W Moody
- Department of Physics and Astronomy, Brigham Young University, Provo, Utah 84602, USA
| | - D A Morozova
- Astronomical Institute, St Petersburg State University, 198504 St Petersburg, Russia
| | - S V Nazarov
- Crimean Astrophysical Observatory RAS, Nauchny 298409, Russia
| | | | - J M Ohlert
- Michael Adrian Observatorium, Astronomie Stiftung Trebur, 65468 Trebur, Germany.,University of Applied Sciences, Technische Hochschule Mittelhessen, 61169 Friedberg, Germany
| | - D N Okhmat
- Crimean Astrophysical Observatory RAS, Nauchny 298409, Russia
| | - E Ovcharov
- Department of Astronomy, Faculty of Physics, University of Sofia, BG-1164 Sofia, Bulgaria
| | - F Pinna
- Instituto de Astrofisica de Canarias (IAC), La Laguna, E-38200 Tenerife, Spain.,Departamento de Astrofisica, Universidad de La Laguna, La Laguna, E-38205 Tenerife, Spain
| | - T A Polakis
- Command Module Observatory, Tempe, Arizona, USA
| | - C Protasio
- Instituto de Astrofisica de Canarias (IAC), La Laguna, E-38200 Tenerife, Spain.,Departamento de Astrofisica, Universidad de La Laguna, La Laguna, E-38205 Tenerife, Spain
| | - T Pursimo
- Nordic Optical Telescope, E-38700 Santa Cruz de La Palma, Spain
| | - F J Redondo-Lorenzo
- Instituto de Astrofisica de Canarias (IAC), La Laguna, E-38200 Tenerife, Spain.,Departamento de Astrofisica, Universidad de La Laguna, La Laguna, E-38205 Tenerife, Spain
| | - N Rizzi
- Osservatorio Astronomico Sirio, I-70013 Castellana Grotte, Italy
| | - G Rodriguez-Coira
- Instituto de Astrofisica de Canarias (IAC), La Laguna, E-38200 Tenerife, Spain.,Departamento de Astrofisica, Universidad de La Laguna, La Laguna, E-38205 Tenerife, Spain
| | - K Sadakane
- Astronomical Institute, Osaka Kyoiku University, Osaka 582-8582, Japan
| | - A C Sadun
- Department of Physics, University of Colorado Denver, Denver, Colorado 80217-3364 USA
| | - M R Samal
- Graduate Institute of Astronomy, National Central University, Jhongli City, Taoyuan County 32001, Taiwan
| | - S S Savchenko
- Astronomical Institute, St Petersburg State University, 198504 St Petersburg, Russia
| | - E Semkov
- Institute of Astronomy and NAO, Bulgarian Academy of Sciences, 1784 Sofia, Bulgaria
| | - B A Skiff
- Lowell Observatory, Flagstaff, Arizona, USA
| | - L Slavcheva-Mihova
- Institute of Astronomy and NAO, Bulgarian Academy of Sciences, 1784 Sofia, Bulgaria
| | - P S Smith
- Steward Observatory, University of Arizona, Tucson, Arizona, USA
| | - I A Steele
- Astrophysics Research Institute, Liverpool John Moores University, Liverpool L3 5RF, UK
| | - A Strigachev
- Institute of Astronomy and NAO, Bulgarian Academy of Sciences, 1784 Sofia, Bulgaria
| | - J Tammi
- Aalto University Metsähovi Radio Observatory, FI-02540 Kylmälä, Finland
| | - C Thum
- Instituto de Radio Astronomía Milimétrica, E-18012 Granada, Spain
| | - M Tornikoski
- Aalto University Metsähovi Radio Observatory, FI-02540 Kylmälä, Finland
| | - Yu V Troitskaya
- Astronomical Institute, St Petersburg State University, 198504 St Petersburg, Russia
| | - I S Troitsky
- Astronomical Institute, St Petersburg State University, 198504 St Petersburg, Russia
| | - A A Vasilyev
- Astronomical Institute, St Petersburg State University, 198504 St Petersburg, Russia
| | - O Vince
- Astronomical Observatory, 11060 Belgrade, Serbia
| |
Collapse
|
17
|
Guarize J, Casiraghi M, Donghi S, Casadio C, Diotti C, Filippi N, Di Tonno C, Midolo V, Maisonneuve P, Brambilla D, Grana CM, Petrella F, Spaggiari L. EBUS-TBNA in PET-positive lymphadenopathies in treated cancer patients. ERJ Open Res 2017; 3:00009-2017. [PMID: 29071277 PMCID: PMC5651815 DOI: 10.1183/23120541.00009-2017] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2017] [Accepted: 08/25/2017] [Indexed: 12/21/2022] Open
Abstract
Mediastinal lymph node enlargement is common in the follow-up of patients with previously treated malignancies. The aim of this study is to assess the role of endobronchial ultrasound (EBUS) transbronchial needle aspiration (TBNA) for cyto-histological evaluation of positron emission tomography with 18fluorodeoxyglucose (PET) positive mediastinal and hilar lymph nodes developed in patients with previous malignancies. All EBUS-TBNA cases performed from January 2012 to May 2016 were retrospective reviewed. Results of EBUS-TBNA in patients with mediastinal and/or hilar lymphadenopathies were analysed. Non-malignant cytopathologies were confirmed with surgical procedures or clinical and radiological follow-up. Among 1780 patients, 176 were included in the analysis. 103 of these (58.5%) had a diagnosis of tumour recurrence whereas 73 (41.5%) had a different diagnosis: 63 (35.8%) had a non-neoplastic diagnosis and 8 patients (4.6%) had a different cell type malignancy. Samples were false-negative in 5 (2.8%) out of 176 patients. The overall sensitivity, specificity, negative predicted value and diagnostic accuracy were 95.7% (95% CI 90.2–98.6%), 100% (95% CI 94.0–100%), 92.3% (95% CI 83.2–96.7%) and 97.2% (95% CI 93.5–98.8%), respectively. EBUS-TBNA demonstrated a pathological diagnosis different from the previous tumour in a large percentage of patients, confirming its strategic role in the management of patients with previously treated malignancies. EBUS-TBNA changes the management of treated cancer patientshttp://ow.ly/vTnh30fBFaE
Collapse
Affiliation(s)
- Juliana Guarize
- Dept of Thoracic Surgery, European Institute of Oncology, Milan, Italy
| | - Monica Casiraghi
- Dept of Thoracic Surgery, European Institute of Oncology, Milan, Italy
| | - Stefano Donghi
- Dept of Thoracic Surgery, European Institute of Oncology, Milan, Italy
| | - Chiara Casadio
- Dept of Pathology, European Institute of Oncology, Milan, Italy
| | - Cristina Diotti
- Dept of Thoracic Surgery, European Institute of Oncology, Milan, Italy
| | - Niccolò Filippi
- Dept of Thoracic Surgery, European Institute of Oncology, Milan, Italy
| | | | - Valeria Midolo
- Dept of Pathology, European Institute of Oncology, Milan, Italy
| | - Patrick Maisonneuve
- Dept of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
| | - Daniela Brambilla
- Dept of Thoracic Surgery, European Institute of Oncology, Milan, Italy
| | | | - Francesco Petrella
- Dept of Thoracic Surgery, European Institute of Oncology, Milan, Italy.,University of Milan, Dept of Haematology and Haematoncology, Milan, Italy
| | - Lorenzo Spaggiari
- Dept of Thoracic Surgery, European Institute of Oncology, Milan, Italy.,University of Milan, Dept of Haematology and Haematoncology, Milan, Italy
| |
Collapse
|
18
|
De Censi A, Cazzaniga M, Casadio C, Chiapparini L, Gandini S, Guerrieri-Gonzaga A, Macis D, Veronesi P, Bonanni B. Association of atypia in ductal lavage and breast cancer risk. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e13040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13040 Background: Atypical hyperplasia is considered a nearly obligate precursor of breast cancer and is associated with a higher risk of developing breast cancer (BC). Attempts to improve early detection of breast cancer and to provide individualized breast cancer risk assessment will greatly benefit from sampling cellular material from the target tissue. Ductal lavage (DL) is a minimally invasive technique which provides adequate material to detect atypical cells in mammary ducts. However, long term data of the association between atypia from and BC risk are lacking .We studied the prevalence of atypia in DL and its ability to predict BC development in women at risk. Methods: From March 2000 to July 2012 we performed DL in a consecutive series of 348 women with median age of 45 (range 19-74) at increased BC risk based on the following characteristics: 5 yrs Gail model > 1.66% or > 10% probability of BRCA mutation (n = 155), history of contralateral BC (CBC, n = 161), presence of a BRCA pathogenic variant (n = 32). We analyzed the presence of atypical cells in the baseline specimens and observed their evolution during follow-up. Results: The procedure was safe and well tolerated in most women, with pain and disconfort preventing the procedure in 5.4% of subjects. Overall, 126 (36%) women had atypia, with a prevalence of 32%, 39%, and 41% in the Gail, CBC and BRCA groups, respectively (p = 0.38). The overall prevalence of atypia considering all visits was 44% (range 36-51). After a median follow up of 6 years, cumulative BC events were 8% in women without atypia versus 14% in those with atypia (log-rank p = 0.08). In the highest risk groups (CBC and BRCA pathogenic variants), the number of BC events was 16 vs 11 in women with or without atypia (21% vs 10%; log-rank p = 0.05, Cox model adjusted for age p = 0.02). Conclusions: Our findings suggest that cytologic atypia in the fluid obtained by DL may predict the onset of BC in high-risk women. The reversal of atypia in DL as a surrogate biomarker of BC risk reduction warrants investigation.
Collapse
Affiliation(s)
- Andrea De Censi
- Division of Medical Oncology, E.O. Galliera Hospital, Genova, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Mattoscio D, Casadio C, Miccolo C, Maffini F, Raimondi A, Tacchetti C, Gheit T, Tagliabue M, Galimberti VE, De Lorenzi F, Pawlita M, Chiesa F, Ansarin M, Tommasino M, Chiocca S. Autophagy regulates UBC9 levels during viral-mediated tumorigenesis. PLoS Pathog 2017; 13:e1006262. [PMID: 28253371 PMCID: PMC5349695 DOI: 10.1371/journal.ppat.1006262] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2016] [Revised: 03/14/2017] [Accepted: 02/26/2017] [Indexed: 02/06/2023] Open
Abstract
UBC9, the sole E2-conjugating enzyme required for SUMOylation, is a key regulator of essential cellular functions and, as such, is frequently altered in cancers. Along these lines, we recently reported that its expression gradually increases during early stages of human papillomavirus (HPV)-mediated cervical lesions transformation. However, a better understanding of how UBC9 is exploited by transforming viral oncoproteins is still needed. In the present study, we show that in human samples HPV drives UBC9 up-regulation also in very early steps of head and neck tumorigenesis, pointing to the important role for UBC9 in the HPV-mediated carcinogenic program. Moreover, using HPV-infected pre-cancerous tissues and primary human keratinocytes as the natural host of the virus, we investigate the pathological meaning and the cellular mechanisms responsible for UBC9 de-regulation in an oncoviral context. Our results show that UBC9 overexpression is promoted by transforming viral proteins to increase host cells' resistance to apoptosis. In addition, ultrastuctural, pharmacological and genetic approaches crucially unveil that UBC9 is physiologically targeted by autophagy in human cells. However, the presence of HPV E6/E7 oncoproteins negatively impacts the autophagic process through selective inhibition of autophagosome-lysosome fusion, finally leading to p53 dependent UBC9 accumulation during viral-induced cellular transformation. Therefore, our study elucidates how UBC9 is manipulated by HPV oncoproteins, details the physiological mechanism by which UBC9 is degraded in cells, and identifies how HPV E6/E7 impact on autophagy. These findings point to UBC9 and autophagy as novel hallmarks of HPV oncogenesis, and open innovative avenues towards the treatment of HPV-related malignancies.
Collapse
Affiliation(s)
- Domenico Mattoscio
- European Institute of Oncology, Department of Experimental Oncology, Milan, Italy
| | - Chiara Casadio
- European Institute of Oncology, Department of Pathology, Milan, Italy
| | - Claudia Miccolo
- European Institute of Oncology, Department of Experimental Oncology, Milan, Italy
| | - Fausto Maffini
- European Institute of Oncology, Department of Pathology, Milan, Italy
| | - Andrea Raimondi
- Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Carlo Tacchetti
- Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy
- Department of Experimental Medicine, University of Genova, Genova, Italy
| | - Tarik Gheit
- Infections and Cancer Biology Group, International Agency for Research on Cancer, Lyon, France
| | - Marta Tagliabue
- European Institute of Oncology, Division of Otolaryngology and Head and Neck Surgery, Milan, Italy
| | | | | | - Michael Pawlita
- Division of Molecular Diagnostics of Oncogenic Infections, Research Program Infection, Inflammation and Cancer, German Cancer Research Center, Heidelberg, Germany
| | - Fausto Chiesa
- European Institute of Oncology, Division of Otolaryngology and Head and Neck Surgery, Milan, Italy
| | - Mohssen Ansarin
- European Institute of Oncology, Division of Otolaryngology and Head and Neck Surgery, Milan, Italy
| | - Massimo Tommasino
- Infections and Cancer Biology Group, International Agency for Research on Cancer, Lyon, France
| | - Susanna Chiocca
- European Institute of Oncology, Department of Experimental Oncology, Milan, Italy
| |
Collapse
|
20
|
Ungaro A, Orsi F, Casadio C, Galdy S, Spada F, Cella CA, Tonno CD, Bonomo G, Vigna PD, Murgioni S, Frezza AM, Fazio N. Successful palliative approach with high-intensity focused ultrasound in a patient with metastatic anaplastic pancreatic carcinoma: a case report. Ecancermedicalscience 2016; 10:635. [PMID: 27170835 PMCID: PMC4854227 DOI: 10.3332/ecancer.2016.635] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2015] [Indexed: 12/14/2022] Open
Abstract
We report a case of a 74-year-old man with a metastatic anaplastic pancreatic carcinoma (APC). After an early tumour progression on first-line chemotherapy with cisplatin and gemcitabine, even though it was badly tolerated, he was treated with a combination of systemic modified FOLFIRI and high-intensity focused ultrasound (HIFU) on the pancreatic mass. A tumour showing partial response with a clinical benefit was obtained. HIFU was preferred to radiotherapy because of its shorter course and minimal side effects, in order to improve the patient's clinical conditions. The patient is currently on chemotherapy, asymptomatic with a good performance status. In referral centres, with specific expertise, HIFU could be safely and successfully combined with systemic chemotherapy for treatment of metastatic pancreatic carcinoma.
Collapse
Affiliation(s)
- Antonio Ungaro
- Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumours, European Institute of Oncology, Milan 20141, Italy
| | - Franco Orsi
- Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumours, European Institute of Oncology, Milan 20141, Italy
| | - Chiara Casadio
- Unit of Diagnostic Cytology, European Institute of Oncology, Milan 20141, Italy
| | - Salvatore Galdy
- Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumours, European Institute of Oncology, Milan 20141, Italy
| | - Francesca Spada
- Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumours, European Institute of Oncology, Milan 20141, Italy
| | - Chiara Alessandra Cella
- Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumours, European Institute of Oncology, Milan 20141, Italy
| | - Clementina Di Tonno
- Unit of Diagnostic Cytology, European Institute of Oncology, Milan 20141, Italy
| | - Guido Bonomo
- Unit of Interventional Radiology, European Institute of Oncology, Milan 20141, Italy
| | - Paolo Della Vigna
- Unit of Interventional Radiology, European Institute of Oncology, Milan 20141, Italy
| | - Sabina Murgioni
- Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumours, European Institute of Oncology, Milan 20141, Italy
| | - Anna Maria Frezza
- Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumours, European Institute of Oncology, Milan 20141, Italy
| | - Nicola Fazio
- Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumours, European Institute of Oncology, Milan 20141, Italy
| |
Collapse
|
21
|
Casadio C, Guarize J, Donghi S, Di Tonno C, Fumagalli C, Vacirca D, Dell’Orto P, De Marinis F, Spaggiari L, Viale G, Barberis M. Molecular Testing for Targeted Therapy in Advanced Non-Small Cell Lung Cancer: Suitability of Endobronchial Ultrasound Transbronchial Needle Aspiration. Am J Clin Pathol 2015; 144:629-34. [PMID: 26386084 DOI: 10.1309/ajcpxgraimb4ctq3] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Abstract
OBJECTIVES Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive procedure that has revolutionized the diagnosis and staging of lung cancer. The goal of the present study was to investigate the yield and applicability of molecular testing in the specimens obtained by EBUS-TBNA from patients with advanced non-small cell lung cancer (NSCLC), comparing the results with a series of patients who underwent diagnostic surgical procedures in the same institution. METHODS The study followed 306 consecutive patients with clinically diagnosed primary lung cancer who had the EBUS-TBNA procedure. EGFR and KRAS mutations were evaluated on cytologic specimens by Sanger sequencing and Cobas real-time polymerase chain reaction, whereas ALK rearrangement was tested by fluorescence in situ hybridization. The results were compared with those obtained from a series of 1,000 NSCLC surgical samples routinely analyzed. RESULTS Molecular testing was possible in 96.9% of the samples obtained by EBUS-TBNA. EGFR (exons 18-21) mutations were found in 16.9%, KRAS mutation (exons 2-3) in 31.6%, and ALK rearrangement in 3.9% of the cases. In the surgical series, the mutations' distribution were 14.8%, 29.0%, and 3.4%, respectively. There were no statistical differences between the two series. CONCLUSIONS Our study demonstrates that EBUS-TBNA can be effectively used not just for diagnosis but also for complete mutational testing.
Collapse
Affiliation(s)
- Chiara Casadio
- Divisions of Pathology, European Institute of Oncology and University of Milan, Milan, Italy
| | - Juliana Guarize
- Thoracic Surgery, European Institute of Oncology and University of Milan, Milan, Italy
| | - Stefano Donghi
- Thoracic Surgery, European Institute of Oncology and University of Milan, Milan, Italy
| | - Clementina Di Tonno
- Divisions of Pathology, European Institute of Oncology and University of Milan, Milan, Italy
| | - Caterina Fumagalli
- Divisions of Pathology, European Institute of Oncology and University of Milan, Milan, Italy
| | - Davide Vacirca
- Divisions of Pathology, European Institute of Oncology and University of Milan, Milan, Italy
| | - Patrizia Dell’Orto
- Divisions of Pathology, European Institute of Oncology and University of Milan, Milan, Italy
| | - Filippo De Marinis
- Thoracic Surgery, European Institute of Oncology and University of Milan, Milan, Italy
| | - Lorenzo Spaggiari
- Thoracic Surgery, European Institute of Oncology and University of Milan, Milan, Italy
| | - Giuseppe Viale
- Divisions of Pathology, European Institute of Oncology and University of Milan, Milan, Italy
| | - Massimo Barberis
- Divisions of Pathology, European Institute of Oncology and University of Milan, Milan, Italy
| |
Collapse
|
22
|
Rena O, Boldorini R, Papalia E, Sacchetti G, Davoli F, Roncon A, Turello D, Massera F, Casadio C. P-176CLINICOPATHOLOGIC RISK FACTORS PREDICTING THE OCCULT NODAL METASTASIS IN T1-2N0M0 NON-SMALL CELL LUNG CANCER PATIENTS STAGED BY POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY. Interact Cardiovasc Thorac Surg 2015. [DOI: 10.1093/icvts/ivv204.176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
23
|
Rena O, Guerrera F, Errico L, Ruffini E, Filosso P, Mossetti C, Papalia E, Lisi E, Ardissone F, Oliaro A, Casadio C. P-175PREDICTIVE VALUE OF 18F-FDG POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY SUVmax IN PATIENTS WITH PULMONARY METASTASIS FROM COLORECTAL CANCER UNDERGOING SURGICAL RESECTION. Interact Cardiovasc Thorac Surg 2015. [DOI: 10.1093/icvts/ivv204.175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
24
|
Costa S, Sideri M, Negri G, Venturoli S, Santini D, Casadio C, Sandri MT, Bucchi L. The predictive value of human papillomavirus testing for the outcome of patients conservatively treated for stage IA squamous cell cervical carcinoma. J Clin Virol 2015; 70:53-57. [PMID: 26305820 DOI: 10.1016/j.jcv.2015.07.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2014] [Revised: 12/29/2014] [Accepted: 07/06/2015] [Indexed: 11/24/2022]
Abstract
BACKGROUND Although it is hypothesised that human papillomavirus (HPV) testing may have a role in surveillance of patients conservatively treated for stage IA squamous cell cervical carcinoma, research on this topic has been minimal. OBJECTIVES To determine: (1) the changes in HPV test result from treatment onward; (2) the time to viral clearance; and (3) the negative predictive value (NPV) and positive predictive value (PPV) of HPV test result for the detection of CIN2 or worse (CIN2+) during follow-up. STUDY DESIGN In a multicentre retrospective follow-up study of a consecutive series (1997-2009) of 91 patients, longitudinal outcome measures were estimated as cumulative probabilities using the Kaplan-Meier method. RESULTS For patients testing HPV-positive at the first follow-up visit (n=44), the probability of change to negative rose from 0 to 0.78 between 7 and 21 months after treatment. For HPV-negative patients (n=47), the probability of change to positive rose to 0.13 between 9 and 26 months. After a median follow-up of 50 months (range, 2-80), the NPV for CIN2+ was 1.00. The PPV was 0.60 (95% confidence interval, 0.43-0.77) after 26 months. The median time to detection was 5 months. CONCLUSIONS If adequately confirmed, these findings would indicate that HPV testing is capable to identify the patients who have had their lesions fully removed, and would make it possible to focus follow-up efforts on a subset of patients at high risk of residual or progressive disease.
Collapse
Affiliation(s)
- Silvano Costa
- Department of Obstetrics and Gynaecology, St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - Mario Sideri
- Preventive Gynaecology Unit, European Institute of Oncology, Milano, Italy
| | - Giovanni Negri
- Department of Pathology, Central Hospital of Bolzano, Bolzano, Italy
| | - Simona Venturoli
- Department of Haematology, Oncology and Laboratory Medicine, Section of Microbiology, St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - Donatella Santini
- Department of Pathology, St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - Chiara Casadio
- Cytology Unit, Department of Pathology, European Institute of Oncology, Milano, Italy
| | - Maria T Sandri
- Division of Laboratory Medicine, European Institute of Oncology, Milano, Italy
| | - Lauro Bucchi
- Romagna Cancer Registry, Romagna Cancer Institute (IRST), Meldola, Forlì, Italy.
| |
Collapse
|
25
|
Montagna E, Bagnardi V, Viale G, Rotmensz N, Sporchia A, Cancello G, Balduzzi A, Galimberti V, Veronesi P, Luini A, Mastropasqua MG, Casadio C, Sangalli C, Goldhirsch A, Colleoni M. Abstract P3-11-07: Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy. Cancer Res 2015. [DOI: 10.1158/1538-7445.sabcs14-p3-11-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
PURPOSE We assessed the frequency of the change in biological features between the diagnostic biopsy and final surgery in breast cancer patients with residual disease after neoadjuvant chemotherapy. We also valued the impact of change on outcome in terms of disease free survival (DFS) and overall survival (OS)
PATIENTS AND METHODS We collected information through the institutional clinical database on all consecutive breast cancer patients treated with neoadjuvant chemotherapy at the European Institute of Oncology (EIO), Milan, Italy, between 1999 and 2011. We selected patients who did not achieved pathological complete response (pCR) at final surgery. All patients had pathological evaluation, including ER, PgR, HER2 protein and ki-67 expression performed at EIO both at diagnostic core biopsy and final surgery.
RESULTS We identified a total of 904 patients. The 5% of patients with ER positive at diagnostic biopsy had ER negative residual tumor at final surgery. For PgR expression, 67% of patients, whose tumors had a PgR> 20% at diagnostic biopsy had a PgR<20% at final surgery. The ki-67 expression changes from >20% to <20% in 40% of patients. At the multivariate analysis the decrease of PgR -immunoreactive cells correlated with improved outcome in terms of DFS (HR 0.73; CI 0.54-1.00 p 0.046). In addition, the decrease of ki-67 expression to < 20% of the cells at final surgery was found to be associated with better outcome both in terms of DFS (HR 0.52; CI 0.40-0.68 p <0.0001) and OS (0.45 CI 0.32-0.64 p<0.0001)
CONCLUSION The decrease of PgR and Ki-67 expression after preoperative chemotherapy have a prognostic role in breast cancer patients with residual disease and should be considered in the adjuvant therapeutic algorithm.
Citation Format: Emilia Montagna, Vincenzo Bagnardi, Giuseppe Viale, Nicole Rotmensz, Andrea Sporchia, Giuseppe Cancello, Alessandra Balduzzi, Viviana Galimberti, Paolo Veronesi, Alberto Luini, Mauro G Mastropasqua, Chiara Casadio, Claudia Sangalli, Aron Goldhirsch, Marco Colleoni. Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-11-07.
Collapse
Affiliation(s)
| | | | - Giuseppe Viale
- 1European Institute of Oncology
- 3University of Milan, School of Medicine
| | | | | | | | | | | | - Paolo Veronesi
- 1European Institute of Oncology
- 3University of Milan, School of Medicine
| | | | | | | | | | | | | |
Collapse
|
26
|
Mattoscio D, Casadio C, Fumagalli M, Sideri M, Chiocca S. The SUMO conjugating enzyme UBC9 as a biomarker for cervical HPV infections. Ecancermedicalscience 2015; 9:534. [PMID: 26015803 PMCID: PMC4435752 DOI: 10.3332/ecancer.2015.534] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2014] [Indexed: 12/14/2022] Open
Abstract
Human papillomaviruses (HPVs) infect stratified epithelium and are the causative agents of cervical cancer, the second most common cause of cancer-related death in women. A critical aspect that still persists in the HPV field is the selection of very sensitive and specific HPV diagnostic assays. Here, we provide evidence that the crucial small ubiquitin-like modifier (SUMO) E2-conjugating enzyme Ubc9 is strongly upregulated in cervical lesions. Ubc9 detection could thus be used in diagnosing and/or monitoring the progression of an HPV oncogenic infection.
Collapse
Affiliation(s)
- Domenico Mattoscio
- European Institute of Oncology, Department of Experimental Oncology, Via Adamello 16, 20139 Milan, Italy ; Equally contributed to this work
| | - Chiara Casadio
- European Institute of Oncology, Department of Pathology, 20141 Milan, Italy ; Equally contributed to this work
| | | | - Mario Sideri
- European Institute of Oncology, Division of Gynecology, 20141 Milan, Italy
| | - Susanna Chiocca
- European Institute of Oncology, Department of Experimental Oncology, Via Adamello 16, 20139 Milan, Italy
| |
Collapse
|
27
|
Montagna E, Bagnardi V, Viale G, Rotmensz N, Sporchia A, Cancello G, Balduzzi A, Galimberti V, Veronesi P, Luini A, Mastropasqua MG, Casadio C, Sangalli C, Goldhirsch A, Colleoni M. Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy. Ann Oncol 2014; 26:307-13. [PMID: 25411418 DOI: 10.1093/annonc/mdu528] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Limited data are available on the prognostic value of changes in the biological features of residual tumours following neoadjuvant therapies in breast cancer patients. PATIENTS AND METHODS We collected information through the institutional clinical database on all consecutive breast cancer patients treated with neoadjuvant chemotherapy at the European Institute of Oncology (IEO), Milan, Italy, between 1999 and 2011. We selected patients who did not achieve pathological complete response at final surgery. All patients had a pathological evaluation, including ER, PgR, HER2 protein and Ki-67 expression carried out at the IEO both at diagnostic core biopsy and at final surgery. RESULTS We identified a total of 904 patients. The 5% of patients who were ER positive at diagnostic biopsy had ER-negative residual tumour at final surgery. For PgR expression, 67% of the patients, whose tumours had a PgR >20% at diagnostic biopsy had a PgR <20% at final surgery. The Ki-67 expression changed from >20% to <20% in 40% of the patients. At the multivariate analysis, the decrease of PgR-immunoreactive cells correlated with improved outcome in terms of disease-free survival (DFS) [hazard ratio (HR) 0.73; 95% confidence interval (CI) 0.54-1.00, P 0.046]. In addition, the decrease of Ki-67 expression to <20% of the cells at final surgery was found to be associated with better outcome both in terms of DFS (HR 0.52; 95% CI 0.40-0.68 P < 0.0001) and overall survival (HR 0.45; 95% CI 0.32-0.64, P < 0.0001). CONCLUSION The decrease of PgR and Ki-67 expression after preoperative chemotherapy has a prognostic role in breast cancer patients with residual disease.
Collapse
Affiliation(s)
- E Montagna
- Division of Medical Senology, European Institute of Oncology, Milan
| | - V Bagnardi
- Department of Quantitative Methods and Statistics, University of Milan-Bicocca, Milan Division of Epidemiology and Biostatistics
| | - G Viale
- Department of Pathology, European Institute of Oncology, Milan School of Medicine, University of Milan, Milan
| | - N Rotmensz
- Division of Epidemiology and Biostatistics
| | - A Sporchia
- Division of Medical Senology, European Institute of Oncology, Milan
| | - G Cancello
- Division of Medical Senology, European Institute of Oncology, Milan
| | - A Balduzzi
- Division of Medical Senology, European Institute of Oncology, Milan
| | | | | | | | | | - C Casadio
- Department of Pathology, European Institute of Oncology, Milan
| | - C Sangalli
- Division of Medical Senology, European Institute of Oncology, Milan
| | - A Goldhirsch
- Program of Senology (Breast Health), European Institute of Oncology, Milan, Italy
| | - M Colleoni
- Division of Medical Senology, European Institute of Oncology, Milan
| |
Collapse
|
28
|
Guarize J, Pardolesi A, Donghi S, Filippi N, Casadio C, Midolo V, Petrella F, Spaggiari L. Endobronchial ultrasound for mediastinal staging in lung cancer patients. Multimed Man Cardiothorac Surg 2014; 2014:mmu021. [PMID: 25332380 DOI: 10.1093/mmcts/mmu021] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has changed the way mediastinal staging is performed in lung cancer patients. EBUS-TBNA is probably the most important non-invasive procedure for mediastinal staging and the currently preferred approach in many reference cancer centres worldwide. EBUS-TBNA is a less invasive technique than mediastinoscopy with low morbidity and no mortality and can be performed in an outpatient setting with excellent results. This study describes the technical aspects of EBUS-TBNA and our personal experience with the procedure.
Collapse
Affiliation(s)
- Juliana Guarize
- Pulmonology, Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
| | | | - Stefano Donghi
- Pulmonology, Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
| | - Niccolò Filippi
- Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
| | - Chiara Casadio
- Division of Pathology, European Institute of Oncology, Milan, Italy
| | - Valeria Midolo
- Division of Pathology, European Institute of Oncology, Milan, Italy
| | - Francesco Petrella
- Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
| | - Lorenzo Spaggiari
- Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy University of Milan, Milan, Italy
| | | |
Collapse
|
29
|
Davoli F, Stella F, Valente G, Vasuri F, Rena O, Massera F, Caroli G, Bini A, Casadio C. F-076 * PROGNOSTIC ROLE OF MICROVESSEL DENSITY IN PT1AN0M0 NON-SMALL-CELL LUNG CANCER. Interact Cardiovasc Thorac Surg 2014. [DOI: 10.1093/icvts/ivu167.76] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Rena O, Santos Pereira P, Boldorini R, Baietto G, Roncon A, Papalia E, Massera F, Turello D, Davoli F, Casadio C. P-166 * PROGNOSTIC VALUE OF THE IASLC/ATS/ERS CLASSIFICATION OF LUNG ADENOCARCINOMA IN RESECTED STAGE I DISEASE IN PURE CAUCASIAN PATIENTS. Interact Cardiovasc Thorac Surg 2014. [DOI: 10.1093/icvts/ivu167.166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Igidbashian S, Boveri S, Radice D, Casadio C, Spolti N, Sandri MT, Sideri M. Performance of self-sampled HPV test in comparison with liquid based cytology. Eur J Obstet Gynecol Reprod Biol 2014; 177:72-6. [PMID: 24768230 DOI: 10.1016/j.ejogrb.2014.03.028] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2013] [Revised: 03/01/2014] [Accepted: 03/31/2014] [Indexed: 11/18/2022]
Abstract
OBJECTIVE Strong evidences shows that HPV testing is more sensitive than cytology in detecting high-grade CIN. HPV test can be performed on samples collected by women themselves by means of self-sampling devices. This study compares the results of self-sampled HPV tests with the results of liquid based cytology (LBC). STUDY DESIGN Seven hundred women scheduled for cervical cytology self-collected a cervicovaginal sample for HPV testing and then underwent a clinician-collected LBC at the European Institute of Oncology. The HPV and LBC results were compared with the McNemar test. RESULTS All HSIL (N=5) resulted hrHPV positive. LBC resulted LSIL or worse in 38 (5.4%) women (out of 700). Self-sampled HPV was positive in 96 women (13.7%). A LSIL or worse LBC result was found in 15 (2.5%) patients, out of the 604 hrHPV negative women and in 23 (24%) patients, out of the 96 hrHPV positive women. Positive cytology after a self-sampled HPV positive result had an Odds Ratio of 12.4 (95% CI: 5.8-26.6). CONCLUSION Self-collected HPV testing identifies a group of women at high risk of positive LBC and high grade SIL.
Collapse
Affiliation(s)
- Sarah Igidbashian
- Preventive Gynaecology Unit, European Institute of Oncology, via Ripamonti 435, 20141 Milano, Italy.
| | - Sara Boveri
- Preventive Gynaecology Unit, European Institute of Oncology, via Ripamonti 435, 20141 Milano, Italy
| | - Davide Radice
- Division of Epidemiology and Biostatistics, European Institute of Oncology, via Ripamonti 435, 20141 Milano, Italy
| | - Chiara Casadio
- Diagnostic Cytology Unit, European Institute of Oncology, via Ripamonti 435, 20141 Milano, Italy
| | - Noemi Spolti
- Preventive Gynaecology Unit, European Institute of Oncology, via Ripamonti 435, 20141 Milano, Italy
| | - Maria T Sandri
- Laboratory Medicine Division, European Institute of Oncology, via Ripamonti 435, 20141 Milano, Italy
| | - Mario Sideri
- Preventive Gynaecology Unit, European Institute of Oncology, via Ripamonti 435, 20141 Milano, Italy
| |
Collapse
|
32
|
Gentilli S, Davoli F, Portigliotti L, Boldorini R, Casadio C, Garavoglia M. Double-stapling technique for transhiatal distal esophageal resection: feasibility test in a cadaver model. Int J Surg 2014; 12:353-6. [PMID: 24463144 DOI: 10.1016/j.ijsu.2014.01.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2013] [Revised: 10/25/2013] [Accepted: 01/16/2014] [Indexed: 10/25/2022]
Abstract
OBJECTIVES To assess the feasibility of a new surgical technique for the resection of the distal third of the esophagus and/or cardias for neoplasm. METHODS This surgical technique consists of two steps: For this purpose we built a stainless steel support bar for the anvil that is thinner than the freespace of a standard linear suturing stapler (TATM). The support bar holds up a push rod that can be adapted to the hooking-unhooking of the anvil. RESULTS We performed our new technique on five cadavers. We did not encounter any difficulty during the procedures. We tested the anastomosis with hydropneumatic assessment without recording any leaks. The esophago-enteric anastomosis was then opened without finding any mechanical defects related to the procedure. CONCLUSION It can often be very difficult to fashion a safe hand-sewn pouch or a purse string around the anvil of an EEATM during the resection of the distal third of the esophagus or the cardias by a trans-hiatal approach. Moreover, there is no standardized procedure to minimize anastomotic leak. To avoid these mechanical problems we designed this innovative procedure, which is considered to be reproducible without significant training.
Collapse
Affiliation(s)
- S Gentilli
- Division of General Surgery, University of Eastern Piedmont, Azienda Ospedaliero-Universitaria "Maggiore della Carità" di Novara, Italy
| | - F Davoli
- Division of Thoracic Surgery, University of Eastern Piedmont, Azienda Ospedaliero-Universitaria "Maggiore della Carità" di Novara, Italy.
| | - L Portigliotti
- Division of General Surgery, University of Eastern Piedmont, Azienda Ospedaliero-Universitaria "Maggiore della Carità" di Novara, Italy
| | - R Boldorini
- Division of Pathology, University of Eastern Piedmont, Azienda Ospedaliero-Universitaria "Maggiore della Carità" di Novara, Italy
| | - C Casadio
- Division of Thoracic Surgery, University of Eastern Piedmont, Azienda Ospedaliero-Universitaria "Maggiore della Carità" di Novara, Italy
| | - M Garavoglia
- Division of General Surgery, University of Eastern Piedmont, Azienda Ospedaliero-Universitaria "Maggiore della Carità" di Novara, Italy
| |
Collapse
|
33
|
Filosso PL, Venuta F, Oliaro A, Ruffini E, Rendina EA, Margaritora S, Casadio C, Terzi A, Rena O, Lococo F, Guerrera F. Thymoma and inter-relationships between clinical variables: a multicentre study in 537 patients. Eur J Cardiothorac Surg 2014; 45:1020-7. [DOI: 10.1093/ejcts/ezt567] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
34
|
Kiehlmann S, Savolainen T, Jorstad SG, Sokolovsky KV, Schinzel FK, Agudo I, Arkharov AA, Benítez E, Berdyugin A, Blinov DA, Bochkarev NG, Borman GA, Burenkov AN, Casadio C, Doroshenko VT, Efimova NV, Fukazawa Y, Gómez JL, Hagen-Thorn VA, Heidt J, Hiriart D, Itoh R, Joshi M, Kimeridze GN, Konstantinova TS, Kopatskaya EN, Korobtsev IV, Kovalev YY, Krajci T, Kurtanidze O, Kurtanidze SO, Larionov VM, Larionova EG, Larionova LV, Lindfors E, López E, Marscher AP, McHardy IM, Molina SN, Morozova DA, Nazarov S, Nikolashvili MG, Nilsson K, Pulatova NG, Reinthal R, Sadun A, Sergeev SG, Sigua LA, Sorcia M, Spiridonova OI, Takalo LO, Taylor B, Troitsky IS, Ugolkova LS, Zensus JA, Zhdanova VE. Analyzing polarization swings in 3C 279. EPJ Web of Conferences 2013. [DOI: 10.1051/epjconf/20136106003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Rena O, Ferretti G, Roncon A, Baietto G, Papalia E, Turello D, Massera F, Davoli F, Casadio C. P-183PERSISTENT LUNG EXPANSION AFTER PLEURAL TALC POUDRAGE IN MALIGNANT PLEURAL MESOTHELIOMA NOT ELIGIBLE FOR SURGICAL RESECTION: AN INDEPENDENT PROGNOSTIC FACTOR. Interact Cardiovasc Thorac Surg 2013. [DOI: 10.1093/icvts/ivt288.183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
36
|
Filosso PL, Rendina A, Guerrera F, Ruffini E, Margaritora S, Casadio C, Terzi A, Lococo F, Rena O, Venuta F. BTOG-115THYMOMA AND INTER-RELATIONSHIPS BETWEEN CLINICAL VARIABLES: A MULTICENTRE STUDY IN 537 PATIENTS. Interact Cardiovasc Thorac Surg 2013. [DOI: 10.1093/icvts/ivt288.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Rena O, Baietto G, Roncon A, Papalia E, Turello D, Massera F, Davoli F, Casadio C. O-013PROGNOSTIC SIGNIFICANCE OF METASTASIS TO SEGMENTAL OR SUBSEGMENTAL LYMPH NODES IN PATIENTS SUBMITTED TO SURGICAL RESECTION OF NON-SMALL CELL LUNG CANCER WITH PATHOLOGIC N1 LYMPH NODE STATUS. Interact Cardiovasc Thorac Surg 2013. [DOI: 10.1093/icvts/ivt288.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Lico R, Casadio C, Gómez J, Giroletti M, Orienti M, Giovannini G, Blasi M, Cotton W, Edwards PG, Fuhrmann L, Jorstad S, Kino M, Kovalev Y, Krichbaum T, Marscher A, Paneque D, Perez-Torres M, Piner G, Sokolovsky K. Very Long Baseline Polarimetric monitoring at 15 GHz of the TeV blazar Markarian 421. EPJ Web of Conferences 2013. [DOI: 10.1051/epjconf/20136107004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Giovannini G, Liuzzo E, Giroletti M, Boccardi B, Tamburri S, Casadio C, Taylor G, Kadler M, Tosti G, Mignano AA. Exploring the bulk of the BL Lac object population: parsec scale radio properties and gamma ray emission. EPJ Web of Conferences 2013. [DOI: 10.1051/epjconf/20136108006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
40
|
Maffini F, Bozzini A, Casadio C, Carinelli S, Pisa E, Possanzini P, Viale G. Ovarian serous papillary carcinoma, metastatic to intramammary lymph-node mimic a primary breast carcinoma on RX mammography. Breast J 2012; 18:484-5. [PMID: 22882656 DOI: 10.1111/j.1524-4741.2012.01286.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Fausto Maffini
- Division of Pathology and Laboratory Medicine Radiological Senology Unit, European Institute of Oncology, Milan, Italy.
| | | | | | | | | | | | | |
Collapse
|
41
|
Mendola C, Cammarota G, Netto R, Cecci G, Pisterna A, Ferrante D, Casadio C, Della Corte F. S(+)-ketamine for control of perioperative pain and prevention of post thoracotomy pain syndrome: a randomized, double-blind study. Minerva Anestesiol 2012; 78:757-766. [PMID: 22441361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
BACKGROUND Post-thoracotomy pain syndrome (PTPS) often complicates the long term outcome of patients; its appearance has been related to perioperative acute pain. The main goal of this study was to evaluate a possible role of S(+)-ketamine in the prevention of PTPS up to 6 months and secondarily its efficacy in the control of perioperative pain when added to thoracic epidural analgesia (TEA) and adjuvants. METHODS Sixty-six patients underwent thoracotomy under general anesthesia. A thoracic epidural catheter was placed for levobupivacaine and sufentanil administration. Thirty-three patients received an i.v. infusion of S(+)-ketamine (Group S(+)K) for 60 hours and 33 patients received i.v. placebo (Group PLAC). Pain was evaluated by Numeric Rating Scale (NRS) during the whole study. All patients had supplementary doses of analgesics, as needed, to have NRS targeted to a value of ≤3 in the 1st and <3 in the following days. Neuropathic Pain Symptom Inventory (NPSI) was evaluated at 1, 3 and 6 months. RESULTS All patients had NRS ≤3 in the early postoperative period and NPSI was less or equal to 1 in the follow-up control for each group with no significant difference at three (P=0.67, OR 0.8 [IC95% 0.3-2.2]) and at six months (P=0.23, OR 1.9 [0.7-5.4]). Incidence of moderate PTPS was 24.6% at 3 and 21.1% at six months while severe PTPS was 6.6% at 3 and 1.8% at six months. No difference was detected in NRS and NPSI at 3 and 6 months between groups. CONCLUSION S(+)-ketamine had no effects in respect to placebo in the prevention of PTPS at 3 and 6 months but had a significant role in maintaining a NRS≤3 in the early postoperative period. A tight control of perioperative pain seems to be associated with a low incidence of moderate and severe PTPS.
Collapse
Affiliation(s)
- C Mendola
- Anesthesia and Intensive Care Service, Maggiore Hospital, School of Medicine, Novara, Italy
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Savoia F, Casadio C, Tabanelli M, Gaddoni G, Savoia F, Patrizi A, Spadola G, Tabanelli M, Spadola G, Lanzanova G, Zago S, Maio V, Giacomoni P. Prurigo nodularis as the first manifestation of a chronic autoimmune cholestatic hepatitis. Int J Dermatol 2011; 50:1588-9. [DOI: 10.1111/j.1365-4632.2009.04368.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
43
|
Sandri MT, Salvatici M, Botteri E, Passerini R, Zorzino L, Rotmensz N, Luini A, Mauro C, Bagnardi V, Cassatella MC, Bottari F, Casadio C, Colleoni M. Prognostic role of CA15.3 in 7942 patients with operable breast cancer. Breast Cancer Res Treat 2011; 132:317-26. [DOI: 10.1007/s10549-011-1863-x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2011] [Accepted: 10/25/2011] [Indexed: 11/24/2022]
|
44
|
Savoia F, Gaddoni G, Casadio C, Spadola G, Patrizi A, Giacomini F, Aldi M. A case of eczematous and vesicular dermatitis during anti-TNFalpha therapy for rheumatoid arthritis. GIORN ITAL DERMAT V 2011; 146:308-309. [PMID: 21785399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
|
45
|
Zecchini S, Bombardelli L, Decio A, Bianchi M, Mazzarol G, Sanguineti F, Aletti G, Maddaluno L, Berezin V, Bock E, Casadio C, Viale G, Colombo N, Giavazzi R, Cavallaro U. The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. EMBO Mol Med 2011; 3:480-94. [PMID: 21739604 PMCID: PMC3377089 DOI: 10.1002/emmm.201100152] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2010] [Revised: 05/04/2011] [Accepted: 05/25/2011] [Indexed: 12/16/2022] Open
Abstract
Epithelial ovarian carcinoma (EOC) is an aggressive neoplasm, which mainly disseminates to organs of the peritoneal cavity, an event mediated by molecular mechanisms that remain elusive. Here, we investigated the expression and functional role of neural cell adhesion molecule (NCAM), a cell surface glycoprotein involved in brain development and plasticity, in EOC. NCAM is absent from normal ovarian epithelium but becomes highly expressed in a subset of human EOC, in which NCAM expression is associated with high tumour grade, suggesting a causal role in cancer aggressiveness. We demonstrate that NCAM stimulates EOC cell migration and invasion in vitro and promotes metastatic dissemination in mice. This pro-malignant function of NCAM is mediated by its interaction with fibroblast growth factor receptor (FGFR). Indeed, not only FGFR signalling is required for NCAM-induced EOC cell motility, but targeting the NCAM/FGFR interplay with a monoclonal antibody abolishes the metastatic dissemination of EOC in mice. Our results point to NCAM-mediated stimulation of FGFR as a novel mechanism underlying EOC malignancy and indicate that this interplay may represent a valuable therapeutic target.
Collapse
Affiliation(s)
- Silvia Zecchini
- IFOM - The FIRC Institute of Molecular Oncology, Milano, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Casadio C, Di Vincenzo S, Chiapparini L, Bonanni B, Cazzaniga M. Breast ductal lavage (DL) and P16 immunocytochemistry. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Betti M, Ferrante D, Padoan M, Guarrera S, Giordano M, Aspesi A, Mirabelli D, Casadio C, Ardissone F, Ruffini E, Betta PG, Libener R, Guaschino R, Matullo G, Piccolini E, Magnani C, Dianzani I. XRCC1 and ERCC1 variants modify malignant mesothelioma risk: a case-control study. Mutat Res 2011; 708:11-20. [PMID: 21277872 DOI: 10.1016/j.mrfmmm.2011.01.001] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2010] [Revised: 12/10/2010] [Accepted: 01/14/2011] [Indexed: 05/20/2023]
Abstract
Malignant pleural mesothelioma (MPM) is a rare aggressive tumor associated with asbestos exposure. The possible role of genetic factors has also been suggested and MPM has been associated with single nucleotide polymorphisms (SNPs) of xenobiotic and oxidative metabolism enzymes. We have identified an association of the DNA repair gene XRCC1 with MPM in the population of Casale Monferrato, a town exposed to high asbestos pollution. To extend this observation we examined 35 SNPs in 15 genes that could be involved in MPM carcinogenicity in 220 MPM patients and 296 controls from two case-control studies conducted in Casale (151 patients, 252 controls) and Turin (69 patients, 44 controls), respectively. Unconditional multivariate logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs). Two DNA repair genes were associated with MPM, i.e. XRCC1 and ERCC1. Considering asbestos-exposed only, the risk increased with the increasing number of XRCC1-399Q alleles (Casale: OR=1.44, 95%CI 1.02-2.03; Casale+Turin: OR=1.34, 95%CI 0.98-1.84) or XRCC1 -77T alleles (Casale+Turin: OR=1.33, 95%CI 0.97-1.81). The XRCC1-TGGGGGAACAGA haplotype was significantly associated with MPM (Casale: OR=1.76, 95%CI 1.04-2.96). Patients heterozygotes for ERCC1 N118N showed an increased OR in all subjects (OR=1.66, 95%CI 1.06-2.60) and in asbestos-exposed only (OR=1.59, 95%CI 1.01-2.50). When the dominant model was considered (i.e. ERCC1 heterozygotes CT plus homozygotes CC versus homozygotes TT) the risk was statistically significant both in all subjects (OR=1.61, 95%CI 1.06-2.47) and in asbestos-exposed only (OR=1.56, 95%CI 1.02-2.40). The combination of ERCC1 N118N and XRCC1 R399Q was statistically significant (Casale: OR=2.02, 95%CI 1.01-4.05; Casale+Turin: OR=2.39, 95%CI 1.29-4.43). The association of MPM with DNA repair genes support the hypothesis that an increased susceptibility to DNA damage may favour asbestos carcinogenicity.
Collapse
Affiliation(s)
- M Betti
- Laboratory of Genetic Pathology, Department of Medical Sciences, University of Piemonte Orientale, Novara, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Sideri M, Minig L, Franchi D, Casadio C, Boveri S, Bocciolone L. Reply to Should diagnostic laparoscopy be conducted before hormonal treatment in early-stage endometrial cancer? Ann Oncol 2011. [DOI: 10.1093/annonc/mdq765] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
49
|
Minig L, Franchi D, Boveri S, Casadio C, Bocciolone L, Sideri M. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Ann Oncol 2011; 22:643-649. [DOI: 10.1093/annonc/mdq463] [Citation(s) in RCA: 96] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
50
|
Tondo F, Saponaro A, Stecco A, Lombardi M, Casadio C, Carriero A. Role of diffusion-weighted imaging in the differential diagnosis of benign and malignant lesions of the chest-mediastinum. Radiol Med 2011; 116:720-33. [PMID: 21293944 DOI: 10.1007/s11547-011-0629-1] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2010] [Accepted: 07/12/2010] [Indexed: 11/24/2022]
Abstract
PURPOSE We retrospectively evaluated the role of diffusion-weighted imaging (DWI) with fat and background signal suppression in the differential diagnosis of benign and malignant lesions of the chest-mediastinum by calculating the mean apparent diffusion coefficient (ADC) values. MATERIALS AND METHODS Thirty-four patients with lung nodules/mediastinal masses underwent magnetic resonance (MR) imaging of the chest with conventional and DWI sequences. All patients had been previously studied with computed tomography (CT). After magnetic resonance (MR) imaging the patients underwent transthoracic CT-guided biopsy or mediastinoscopy. After the histopathological diagnosis had been obtained, the lesions were retrospectively divided into five groups: adenocarcinomas (n=16), squamous cell carcinomas (n=12), chronic pneumonias (n=2), malignant mediastinal tumours (n=2) and typical carcinoids (n=2). We compared ADC values in the different lesion groups using the Mann-Whitney U test. RESULTS There were statistically significant differences (p<0.05) between ADC values of benign and malignant lesions. Using an ADC value of 1.25×10⁻³ mm²/s as a threshold, we were able to differentiate malignant from benign lesions with 91% diagnostic accuracy, 90% sensitivity, 100% specificity, 100% positive predictive value and 57% negative predictive value. CONCLUSIONS Short-tau inversion-recovery echo-planar imaging (STIR-EPI) sequences applied to the chest-mediastinum provided potentially useful images for the differential diagnosis of benign and malignant lesions.
Collapse
Affiliation(s)
- F Tondo
- SCDU Radiologia, Università del Piemonte Orientale A. Avogadro, C.so Mazzini 18, 28100, Novara, Italy.
| | | | | | | | | | | |
Collapse
|